[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Efavirenz.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be decreased when combined with Efavirenz.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Efavirenz.]
[J01EC02, sulfadiazine, The metabolism of Sulfadiazine can be decreased when combined with Efavirenz.]
[J01EC01, sulfamethoxazole, The metabolism of Sulfamethoxazole can be decreased when combined with Efavirenz.]
[M04AB02, sulfinpyrazone, The metabolism of Sulfinpyrazone can be decreased when combined with Efavirenz.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Efavirenz.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Efavirenz.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Efavirenz is combined with Sulthiame.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Efavirenz.]
[N06DA01, tacrine, The metabolism of Tacrine can be decreased when combined with Efavirenz.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Efavirenz.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Efavirenz.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Efavirenz.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Efavirenz.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Efavirenz.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Tetracycline can be decreased when combined with Efavirenz.]
[N05AE05, lurasidone, The metabolism of Lurasidone can be decreased when combined with Efavirenz.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Efavirenz.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Apomorphine.]
[L04AX02, thalidomide, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Efavirenz.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Efavirenz.]
[P02CA02, thiabendazole, The metabolism of Thiabendazole can be decreased when combined with Efavirenz.]
[A11DA01, thiamine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Thiamine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Efavirenz.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Efavirenz.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Efavirenz.]
[N05CA19, thiopental, The metabolism of Thiopental can be increased when combined with Efavirenz.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Efavirenz is combined with Thiothixene.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Efavirenz is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Efavirenz can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Tilidine.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Efavirenz.]
[P01AB02, tinidazole, The metabolism of Tinidazole can be decreased when combined with Efavirenz.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be decreased when combined with Efavirenz.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Efavirenz.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Efavirenz is combined with Tolperisone.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Efavirenz.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Efavirenz.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Efavirenz.]
[S01BA05, triamcinolone, The metabolism of Triamcinolone can be decreased when combined with Efavirenz.]
[C03DB02, triamterene, The metabolism of Triamterene can be decreased when combined with Efavirenz.]
[N05CD05, triazolam, The metabolism of Triazolam can be decreased when combined with Efavirenz.]
[A03AB12, mepenzolate, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Trifluoperazine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Efavirenz is combined with Trifluperidol.]
[N05AA05, triflupromazine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, The serum concentration of Trimebutine can be decreased when it is combined with Efavirenz.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Alimemazine.]
[N03AC02, trimethadione, The serum concentration of Trimethadione can be decreased when it is combined with Efavirenz.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Efavirenz.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Efavirenz.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Efavirenz.]
[A03BB01, butylscopolamine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Troleandomycin can be decreased when combined with Efavirenz.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Efavirenz.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Efavirenz.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Tubocurarine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Efavirenz.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Efavirenz.]
[L02BX03, abiraterone, The serum concentration of Efavirenz can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Linagliptin can be decreased when combined with Efavirenz.]
[J05AP03, boceprevir, The serum concentration of Boceprevir can be decreased when it is combined with Efavirenz.]
[J05AP02, telaprevir, The serum concentration of Telaprevir can be decreased when it is combined with Efavirenz.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Efavirenz.]
[N03AX21, ezogabine, The metabolism of Ezogabine can be increased when combined with Efavirenz.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be decreased when combined with Efavirenz.]
[R03AC18, indacaterol, The metabolism of Indacaterol can be decreased when combined with Efavirenz.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be decreased when combined with Efavirenz.]
[C08DA01, verapamil, The serum concentration of Verapamil can be decreased when it is combined with Efavirenz.]
[N06AX09, viloxazine, The metabolism of Efavirenz can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Efavirenz.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Efavirenz.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Efavirenz.]
[A11HA03, vitamin E, The metabolism of Vitamin E can be decreased when combined with Efavirenz.]
[B01AA03, warfarin, The metabolism of Warfarin can be decreased when combined with Efavirenz.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Efavirenz.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be decreased when combined with Efavirenz.]
[J05AE02, indinavir, The serum concentration of Indinavir can be decreased when it is combined with Efavirenz.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Efavirenz is combined with Levetiracetam.]
[L01EC01, vemurafenib, The serum concentration of Efavirenz can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Efavirenz.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Efavirenz.]
[R03DC01, zafirlukast, The metabolism of Zafirlukast can be decreased when combined with Efavirenz.]
[A02BC04, rabeprazole, The metabolism of Rabeprazole can be decreased when combined with Efavirenz.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Efavirenz.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be decreased when combined with Efavirenz.]
[N02BA01, aspirin, The metabolism of Acetylsalicylic acid can be decreased when combined with Efavirenz.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Efavirenz.]
[G04BD07, tolterodine, The serum concentration of Tolterodine can be increased when it is combined with Efavirenz.]
[C07AB03, atenolol, Atenolol may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[L03AB11, peginterferon alfa-2a, The metabolism of Efavirenz can be decreased when combined with Peginterferon alfa-2a.]
[J02AC03, voriconazole, The metabolism of Voriconazole can be increased when combined with Efavirenz.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Efavirenz is combined with Atracurium.]
[S01FA01, atropine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Efavirenz.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Efavirenz.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Efavirenz.]
[H02AB11, prednylidene, The metabolism of Prednylidene can be decreased when combined with Efavirenz.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Efavirenz.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Efavirenz.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Efavirenz.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Efavirenz.]
[G04BD12, mirabegron, The metabolism of Mirabegron can be decreased when combined with Efavirenz.]
[V03AX03, cobicistat, The metabolism of Cobicistat can be decreased when combined with Efavirenz.]
[J05AJ02, elvitegravir, The metabolism of Elvitegravir can be decreased when combined with Efavirenz.]
[L02BB04, enzalutamide, The serum concentration of Efavirenz can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Efavirenz.]
[L04AA31, teriflunomide, The serum concentration of Efavirenz can be decreased when it is combined with Teriflunomide.]
[H02AA01, aldosterone, The metabolism of Aldosterone can be decreased when combined with Efavirenz.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Efavirenz.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Efavirenz is combined with Barbital.]
[J05AE04, nelfinavir, The metabolism of Efavirenz can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Efavirenz.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Efavirenz is combined with Rasagiline.]
[C08CA13, lercanidipine, The serum concentration of Lercanidipine can be decreased when it is combined with Efavirenz.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Efavirenz is combined with Mosapride.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Efavirenz.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Efavirenz.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Efavirenz.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be decreased when combined with Efavirenz.]
[R06AC06, thonzylamine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Darifenacin can be decreased when combined with Efavirenz.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Efavirenz is combined with Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Efavirenz.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Efavirenz.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Efavirenz.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Efavirenz.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Efavirenz.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Efavirenz.]
[J04AK05, bedaquiline, The metabolism of Bedaquiline can be decreased when combined with Efavirenz.]
[C04AX11, bencyclane, The serum concentration of Bencyclane can be decreased when it is combined with Efavirenz.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Efavirenz.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Efavirenz.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Efavirenz.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Efavirenz is combined with Benperidol.]
[A10BK02, canagliflozin, The serum concentration of Canagliflozin can be decreased when it is combined with Efavirenz.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Gemifloxacin.]
[M04AB03, benzbromarone, Efavirenz may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Efavirenz.]
[A06AX06, tegaserod, The metabolism of Efavirenz can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Benzocaine.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Efavirenz.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Efavirenz is combined with Naratriptan.]
[L04AA18, everolimus, The serum concentration of Everolimus can be decreased when it is combined with Efavirenz.]
[N04AC01, benztropine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Dabrafenib can be increased when it is combined with Efavirenz.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Efavirenz is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Efavirenz.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be decreased when it is combined with Efavirenz.]
[C08EA02, bepridil, The risk or severity of ventricular arrhythmias can be increased when Efavirenz is combined with Bepridil.]
[C02KX05, riociguat, The serum concentration of Riociguat can be increased when it is combined with Efavirenz.]
[A05AA03, cholic acid, Cholic Acid may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[G03XC02, bazedoxifene, The metabolism of Bazedoxifene can be increased when combined with Efavirenz.]
[C02KX04, macitentan, The metabolism of Macitentan can be decreased when combined with Efavirenz.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Efavirenz.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Efavirenz.]
[G03AC08, etonogestrel, The therapeutic efficacy of Etonogestrel can be decreased when used in combination with Efavirenz.]
[N03AF04, eslicarbazepine, The metabolism of Eslicarbazepine can be increased when combined with Efavirenz.]
[J05AP05, simeprevir, The metabolism of Simeprevir can be decreased when combined with Efavirenz.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Efavirenz is combined with Vigabatrin.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Efavirenz.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Efavirenz.]
[A16AA07, metreleptin, The metabolism of Efavirenz can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Apremilast can be decreased when combined with Efavirenz.]
[S03BA03, betamethasone, The metabolism of Betamethasone can be decreased when combined with Efavirenz.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Efavirenz.]
[C10AB02, bezafibrate, The metabolism of Bezafibrate can be decreased when combined with Efavirenz.]
[L04AC11, siltuximab, The metabolism of Efavirenz can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Efavirenz.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Efavirenz.]
[A03BA03, hyoscyamine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Efavirenz.]
[L01XH04, belinostat, The metabolism of Belinostat can be increased when combined with Efavirenz.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Efavirenz.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Efavirenz is combined with Alfaxalone.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Efavirenz.]
[D11AA01, glycopyrronium, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Efavirenz.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Acepromazine.]
[A06AH03, naloxegol, The metabolism of Naloxegol can be decreased when combined with Efavirenz.]
[N04AA02, biperiden, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[A11HA08, tocophersolan, The metabolism of Tocofersolan can be decreased when combined with Efavirenz.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Efavirenz.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Efavirenz.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Efavirenz.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Efavirenz.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be decreased when combined with Efavirenz.]
[N06AX11, mirtazapine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Efavirenz can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Efavirenz.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Efavirenz.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Efavirenz.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Efavirenz.]
[A03AA09, difemerine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[C01EB17, ivabradine, Ivabradine may increase the QTc-prolonging activities of Efavirenz.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Efavirenz.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Efavirenz.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Efavirenz.]
[A04AD14, rolapitant, The metabolism of Rolapitant can be increased when combined with Efavirenz.]
[G02CX02, flibanserin, The metabolism of Flibanserin can be decreased when combined with Efavirenz.]
[N05AX15, cariprazine, The metabolism of Cariprazine can be decreased when combined with Efavirenz.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Efavirenz is combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Efavirenz.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Efavirenz.]
[J02AC05, isavuconazole, The metabolism of Isavuconazole can be decreased when combined with Efavirenz.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Efavirenz.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be decreased when combined with Efavirenz.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Efavirenz.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Efavirenz.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Efavirenz.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Efavirenz.]
[A10BB31, acetohexamide, The metabolism of Acetohexamide can be decreased when combined with Efavirenz.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Efavirenz.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Efavirenz.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be decreased when combined with Efavirenz.]
[J05AP11, grazoprevir, The metabolism of Grazoprevir can be decreased when combined with Efavirenz.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Efavirenz is combined with Aprobarbital.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Efavirenz.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Efavirenz.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Efavirenz is combined with Bromazepam.]
[N04BC01, bromocriptine, The serum concentration of Bromocriptine can be increased when it is combined with Efavirenz.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Efavirenz.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Efavirenz is combined with Amineptine.]
[C08CA01, amlodipine, The serum concentration of Amlodipine can be decreased when it is combined with Efavirenz.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Efavirenz.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Efavirenz is combined with Aniracetam.]
[A05AA04, obeticholic acid, The metabolism of Efavirenz can be decreased when combined with Obeticholic acid.]
[N01BB01, bupivacaine, The metabolism of Bupivacaine can be decreased when combined with Efavirenz.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Efavirenz.]
[N07BC01, buprenorphine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Efavirenz.]
[N05BE01, buspirone, The metabolism of Buspirone can be decreased when combined with Efavirenz.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Efavirenz.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Artemether can be increased when combined with Efavirenz.]
[M02AA03, clofezone, The metabolism of Rabeprazole can be decreased when combined with Efavirenz.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Efavirenz.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Efavirenz.]
[S01GX07, azelastine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Rucaparib can be decreased when combined with Efavirenz.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be decreased when combined with Efavirenz.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be decreased when combined with Efavirenz.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Efavirenz.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Efavirenz.]
[N02BF02, pregabalin, The therapeutic efficacy of Efavirenz can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Efavirenz is combined with Beclamide.]
[N06BC01, caffeine, The metabolism of Efavirenz can be decreased when combined with Caffeine.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Efavirenz is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Calcitriol can be decreased when combined with Efavirenz.]
[J05AF06, abacavir, The metabolism of Abacavir can be increased when combined with Efavirenz.]
[J05AE09, tipranavir, The metabolism of Tipranavir can be decreased when combined with Efavirenz.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Efavirenz.]
[L04AB02, infliximab, The metabolism of Efavirenz can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be decreased when combined with Efavirenz.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Efavirenz.]
[N04BD03, safinamide, The metabolism of Safinamide can be decreased when combined with Efavirenz.]
[J01MA23, delafloxacin, The metabolism of Delafloxacin can be increased when combined with Efavirenz.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Acetylcholine.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be decreased when combined with Efavirenz.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Efavirenz.]
[L01EH02, neratinib, The serum concentration of Neratinib can be increased when it is combined with Efavirenz.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Efavirenz.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Efavirenz.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Efavirenz.]
[C07AB07, bisoprolol, The metabolism of Bisoprolol can be decreased when combined with Efavirenz.]
[S01AA13, fusidic acid, The metabolism of Fusidic acid can be decreased when combined with Efavirenz.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Efavirenz.]
[N04AA11, bornaprine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Efavirenz is combined with Bromperidol.]
[N05CD09, brotizolam, The metabolism of Brotizolam can be decreased when combined with Efavirenz.]
[R03BA02, budesonide, The metabolism of Budesonide can be decreased when combined with Efavirenz.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Efavirenz.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Efavirenz is combined with Butobarbital.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Efavirenz.]
[N01BX04, capsaicin, The metabolism of Efavirenz can be increased when combined with Capsaicin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Efavirenz is combined with Vinylbital.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Efavirenz.]
[V04CD06, macimorelin, The metabolism of Macimorelin can be decreased when combined with Efavirenz.]
[L02BB05, apalutamide, The metabolism of Apalutamide can be decreased when combined with Efavirenz.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be decreased when combined with Efavirenz.]
[A03AA03, camylofine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Carbinoxamine.]
[L03AB06, interferon alfa-n1, The metabolism of Efavirenz can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The serum concentration of Carvedilol can be decreased when it is combined with Efavirenz.]
[B02BX09, fostamatinib, The metabolism of Fostamatinib can be decreased when combined with Efavirenz.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be decreased when combined with Efavirenz.]
[L04AA37, baricitinib, The metabolism of Baricitinib can be decreased when combined with Efavirenz.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Efavirenz.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be increased when combined with Efavirenz.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Efavirenz.]
[H01CC03, elagolix, The metabolism of Elagolix can be increased when combined with Efavirenz.]
[L01XX62, ivosidenib, The metabolism of Ivosidenib can be decreased when combined with Efavirenz.]
[A16AX14, migalastat, The metabolism of Migalastat can be increased when combined with Efavirenz.]
[N03AX17, stiripentol, The metabolism of Efavirenz can be decreased when combined with Stiripentol.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Efavirenz.]
[J01AA13, eravacycline, The metabolism of Eravacycline can be decreased when combined with Efavirenz.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Efavirenz.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Efavirenz.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Efavirenz.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Efavirenz is combined with Carbromal.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Efavirenz.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Efavirenz.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Efavirenz.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Efavirenz.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Efavirenz.]
[R03BB08, revefenacin, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Efavirenz.]
[L04AA39, emapalumab, The metabolism of Efavirenz can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Carmustine can be decreased when combined with Efavirenz.]
[L01EX12, larotrectinib, The metabolism of Larotrectinib can be decreased when combined with Efavirenz.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be decreased when combined with Efavirenz.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Efavirenz.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Amifampridine.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Efavirenz.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Efavirenz.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Efavirenz.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Efavirenz is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Efavirenz.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Esketamine.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Efavirenz is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Clarithromycin can be decreased when combined with Efavirenz.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Efavirenz is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Efavirenz is combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Efavirenz.]
[N05BA09, clobazam, The metabolism of Clobazam can be decreased when combined with Efavirenz.]
[H02AB14, cloprednol, The metabolism of Cloprednol can be decreased when combined with Efavirenz.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Efavirenz is combined with Cloxazolam.]
[C09CA06, candesartan, The metabolism of Candesartan can be decreased when combined with Efavirenz.]
[L04AB01, etanercept, The metabolism of Efavirenz can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Cortivazol can be decreased when combined with Efavirenz.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be decreased when combined with Efavirenz.]
[L01FX14, polatuzumab vedotin, The risk or severity of adverse effects can be increased when Efavirenz is combined with Polatuzumab vedotin.]
[J01DC04, cefaclor, Efavirenz may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[L01XX66, selinexor, The metabolism of Selinexor can be decreased when combined with Efavirenz.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be decreased when it is combined with Efavirenz.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Efavirenz.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Cyamemazine.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Efavirenz.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Efavirenz.]
[L04AA44, upadacitinib, The metabolism of Upadacitinib can be decreased when combined with Efavirenz.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Efavirenz.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Efavirenz.]
[N07XX11, pitolisant, The serum concentration of Efavirenz can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The serum concentration of Pretomanid can be increased when it is combined with Efavirenz.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Efavirenz.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Efavirenz.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be decreased when combined with Efavirenz.]
[A10AE03, insulin, regular, pork, The metabolism of Efavirenz can be increased when combined with Insulin pork.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Efavirenz.]
[H02AB13, deflazacort, The serum concentration of Deflazacort can be decreased when it is combined with Efavirenz.]
[G03DB05, demegestone, The metabolism of Demegestone can be decreased when combined with Efavirenz.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Efavirenz.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Efavirenz.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be decreased when combined with Efavirenz.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Efavirenz.]
[N03AX25, cenobamate, The serum concentration of Efavirenz can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Efavirenz can be increased when it is combined with Givosiran.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Efavirenz.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Efavirenz.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Efavirenz.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Dexchlorpheniramine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Dezocine.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Efavirenz.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Efavirenz.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Efavirenz.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Efavirenz.]
[M01AX21, diacetylrhein, The metabolism of Efavirenz can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be decreased when combined with Efavirenz.]
[J05AB16, remdesivir, The metabolism of Remdesivir can be decreased when combined with Efavirenz.]
[S01AE06, gatifloxacin, The metabolism of Efavirenz can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The serum concentration of Osilodrostat can be increased when it is combined with Efavirenz.]
[J05AE05, amprenavir, The serum concentration of the active metabolites of Amprenavir can be reduced when Amprenavir is used in combination with Efavirenz resulting in a loss in efficacy.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Efavirenz is combined with Frovatriptan.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be increased when combined with Efavirenz.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Efavirenz.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Efavirenz is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Efavirenz.]
[G03DB08, dienogest, The metabolism of Dienogest can be decreased when combined with Efavirenz.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Efavirenz is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Efavirenz.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Efavirenz.]
[M01AH02, rofecoxib, The metabolism of Rofecoxib can be decreased when combined with Efavirenz.]
[L01XF03, bexarotene, The metabolism of Bexarotene can be decreased when combined with Efavirenz.]
[C08CA16, clevidipine, The serum concentration of Clevidipine can be decreased when it is combined with Efavirenz.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Efavirenz.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Efavirenz is combined with Valpromide.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Efavirenz.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Efavirenz.]
[L01EN02, pemigatinib, The metabolism of Pemigatinib can be increased when combined with Efavirenz.]
[L01FX17, sacituzumab govitecan, The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Efavirenz.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Efavirenz.]
[A03AA08, dihexyverine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Efavirenz.]
[D07XB03, fluprednidene, The metabolism of Fluprednidene can be decreased when combined with Efavirenz.]
[P01BE01, artemisinin, The metabolism of Artemisinin can be decreased when combined with Efavirenz.]
[G04BD09, trospium, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[L01EX19, ripretinib, The serum concentration of Ripretinib can be increased when it is combined with Efavirenz.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Efavirenz.]
[N05CM02, chlormethiazole, The metabolism of Clomethiazole can be decreased when combined with Efavirenz.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Efavirenz is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Dyclonine.]
[L01XX69, lurbinectedin, The serum concentration of Lurbinectedin can be decreased when it is combined with Efavirenz.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be decreased when it is combined with Efavirenz.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Efavirenz.]
[J05AX29, fostemsavir, The metabolism of Fostemsavir can be decreased when combined with Efavirenz.]
[P01BB01, proguanil, The serum concentration of Cycloguanil, an active metabolite of Proguanil, can be decreased when used in combination with Efavirenz.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Efavirenz is combined with Remimazolam.]
[N07XX04, sodium oxybate, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[L01FX15, belantamab mafodotin, Efavirenz may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L04AC19, satralizumab, The serum concentration of Efavirenz can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Efavirenz is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Efavirenz.]
[L01EX23, pralsetinib, The serum concentration of Pralsetinib can be increased when it is combined with Efavirenz.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be decreased when combined with Efavirenz.]
[N05AA01, chlorpromazine, The metabolism of Chlorpromazine can be decreased when combined with Efavirenz.]
[A10BB02, chlorpropamide, The metabolism of Chlorpropamide can be decreased when combined with Efavirenz.]
[N05AF03, chlorprothixene, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Efavirenz.]
[A11CC05, cholecalciferol, The metabolism of Cholecalciferol can be decreased when combined with Efavirenz.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Etifoxine.]
[N02BA03, choline salicylate, The risk or severity of adverse effects can be increased when Efavirenz is combined with Choline salicylate.]
[N06BX18, vinpocetine, The serum concentration of Vinpocetine can be decreased when it is combined with Efavirenz.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Efavirenz is combined with Ethyl loflazepate.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be decreased when combined with Efavirenz.]
[M01AB08, etodolac, The metabolism of Etodolac can be decreased when combined with Efavirenz.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Lonafarnib can be decreased when combined with Efavirenz.]
[L02BX04, relugolix, The metabolism of Relugolix can be decreased when combined with Efavirenz.]
[J05AJ04, cabotegravir, The metabolism of Cabotegravir can be increased when combined with Efavirenz.]
[L04AD03, voclosporin, The metabolism of Voclosporin can be decreased when combined with Efavirenz.]
[P03AX07, abametapir, The serum concentration of Efavirenz can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Efavirenz.]
[V03AF12, trilaciclib, The metabolism of Efavirenz can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Efavirenz is combined with Febarbamate.]
[N03AX10, felbamate, The metabolism of Felbamate can be decreased when combined with Efavirenz.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Efavirenz.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Efavirenz.]
[J01MB07, flumequine, The metabolism of Efavirenz can be decreased when combined with Flumequine.]
[R03BA03, flunisolide, The metabolism of Flunisolide can be decreased when combined with Efavirenz.]
[S02BA08, fluocinolone acetonide, The metabolism of Fluocinolone acetonide can be decreased when combined with Efavirenz.]
[S01JA01, fluorescein, Efavirenz may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Efavirenz.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Efavirenz.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Efavirenz.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Efavirenz is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Efavirenz can be increased when it is combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Efavirenz is combined with Gabapentin.]
[N07CA02, cinnarizine, The serum concentration of Cinnarizine can be decreased when it is combined with Efavirenz.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Efavirenz can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Efavirenz.]
[S03AA07, ciprofloxacin, The metabolism of Efavirenz can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The metabolism of Efavirenz can be decreased when combined with Cisplatin.]
[N06AB04, citalopram, The serum concentration of Citalopram can be increased when it is combined with Efavirenz.]
[H01AC07, somapacitan, The metabolism of Efavirenz can be increased when combined with Somapacitan.]
[J02AX07, ibrexafungerp, The serum concentration of Ibrexafungerp can be decreased when it is combined with Efavirenz.]
[C03DA05, finerenone, The serum concentration of the active metabolites of Finerenone can be increased when Finerenone is used in combination with Efavirenz.]
[L04AA48, belumosudil, The metabolism of Belumosudil can be decreased when combined with Efavirenz.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Efavirenz is combined with Fexinidazole.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Efavirenz.]
[H01AC09, lonapegsomatropin, The metabolism of Efavirenz can be increased when combined with Lonapegsomatropin.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Mobocertinib.]
[L01FX23, tisotumab vedotin, The metabolism of Tisotumab vedotin can be decreased when combined with Efavirenz.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Efavirenz.]
[L04AA59, avacopan, The metabolism of Avacopan can be decreased when combined with Efavirenz.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Efavirenz.]
[A10BB12, glimepiride, The metabolism of Glimepiride can be decreased when combined with Efavirenz.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Efavirenz.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Efavirenz.]
[N06AX25, St. John's wort extract, The serum concentration of Efavirenz can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Asciminib can be increased when it is combined with Efavirenz.]
[L02BG06, exemestane, The metabolism of Exemestane can be decreased when combined with Efavirenz.]
[J05AX10, maribavir, The metabolism of Maribavir can be decreased when combined with Efavirenz.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Efavirenz.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Efavirenz.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Efavirenz.]
[C10AB01, clofibrate, The metabolism of Clofibrate can be decreased when combined with Efavirenz.]
[B06AX04, mitapivat, The metabolism of Mitapivat can be decreased when combined with Efavirenz.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Pacritinib can be increased when it is combined with Efavirenz.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Efavirenz.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Efavirenz.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Efavirenz.]
[C01EB24, mavacamten, The serum concentration of Mavacamten can be increased when it is combined with Efavirenz.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Efavirenz.]
[N03AX27, ganaxolone, The metabolism of Ganaxolone can be increased when combined with Efavirenz.]
[A05BA08, glycyrrhizic acid, Efavirenz may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Clothiapine.]
[N05BA21, clotiazepam, The metabolism of Clotiazepam can be decreased when combined with Efavirenz.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Efavirenz.]
[A04AA02, granisetron, The metabolism of Granisetron can be decreased when combined with Efavirenz.]
[J05AX31, lenacapavir, The metabolism of Lenacapavir can be increased when combined with Efavirenz.]
[L01XX77, adagrasib, The serum concentration of Adagrasib can be increased when it is combined with Efavirenz.]
[N05AH02, clozapine, The metabolism of Clozapine can be decreased when combined with Efavirenz.]
[L01EN04, futibatinib, The metabolism of Futibatinib can be decreased when combined with Efavirenz.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Efavirenz is combined with Halazepam.]
[H01AC08, somatrogon, The metabolism of Efavirenz can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Cocaine.]
[M09AX11, palovarotene, The serum concentration of Palovarotene can be increased when it is combined with Efavirenz.]
[C02KB01, metyrosine, Efavirenz may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Efavirenz can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The metabolism of Codeine can be decreased when combined with Efavirenz.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Efavirenz is combined with Hexafluronium.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Efavirenz.]
[A03AB10, hexocyclium, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[L04AA13, leflunomide, The serum concentration of Efavirenz can be decreased when it is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Efavirenz is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Efavirenz is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Efavirenz is combined with Ifenprodil.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Efavirenz.]
[J01FA15, telithromycin, The metabolism of Telithromycin can be decreased when combined with Efavirenz.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Efavirenz.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Desloratadine.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be decreased when combined with Efavirenz.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Efavirenz.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Efavirenz.]
[J02AC02, itraconazole, The metabolism of Itraconazole can be decreased when combined with Efavirenz.]
[S01AD03, acyclovir, The metabolism of Acyclovir can be decreased when combined with Efavirenz.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Emedastine.]
[N05BA10, ketazolam, The metabolism of Ketazolam can be decreased when combined with Efavirenz.]
[L02BA03, fulvestrant, The metabolism of Fulvestrant can be increased when combined with Efavirenz.]
[L01EA01, imatinib, The serum concentration of Imatinib can be increased when it is combined with Efavirenz.]
[J02AC04, posaconazole, The serum concentration of Posaconazole can be decreased when it is combined with Efavirenz.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be decreased when combined with Efavirenz.]
[C08CA09, lacidipine, The serum concentration of Lacidipine can be decreased when it is combined with Efavirenz.]
[N03AX09, lamotrigine, The metabolism of Lamotrigine can be increased when combined with Efavirenz.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Efavirenz.]
[S01BA03, cortisone, The metabolism of Cortisone can be decreased when combined with Efavirenz.]
[N07BC04, lofexidine, The therapeutic efficacy of Efavirenz can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Lomefloxacin.]
[R06AX13, loratadine, The metabolism of Loratadine can be decreased when combined with Efavirenz.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Efavirenz is combined with Lormetazepam.]
[C08CA11, manidipine, The serum concentration of Manidipine can be decreased when it is combined with Efavirenz.]
[A03AA04, mebeverine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Medifoxamine.]
[H02AB15, meprednisone, The metabolism of Meprednisone can be decreased when combined with Efavirenz.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Efavirenz.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Adenosine.]
[N04AA03, methixene, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, The serum concentration of Cyclandelate can be decreased when it is combined with Efavirenz.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Efavirenz is combined with Cyclobarbital.]
[C03DA04, eplerenone, The metabolism of Eplerenone can be decreased when combined with Efavirenz.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Melperone.]
[J01FA03, midecamycin, The metabolism of Midecamycin can be decreased when combined with Efavirenz.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Efavirenz.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Minaprine.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be decreased when it is combined with Efavirenz.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Efavirenz is combined with Moclobemide.]
[N06BA07, modafinil, The metabolism of Efavirenz can be increased when combined with Armodafinil.]
[R06AX02, cyproheptadine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Efavirenz.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Efavirenz.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be decreased when combined with Efavirenz.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Cytarabine.]
[J05AF10, entecavir, The metabolism of Entecavir can be decreased when combined with Efavirenz.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Efavirenz.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Efavirenz.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be decreased when combined with Efavirenz.]
[G03XA01, danazol, The metabolism of Efavirenz can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Efavirenz is combined with Dantrolene.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Efavirenz.]
[L01DB02, daunorubicin, Efavirenz may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Efavirenz is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be decreased when combined with Efavirenz.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Efavirenz is combined with Nordazepam.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Efavirenz.]
[N06AX06, nefazodone, The metabolism of Nefazodone can be decreased when combined with Efavirenz.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Niaprazine.]
[L02BB02, nilutamide, The metabolism of Nilutamide can be decreased when combined with Efavirenz.]
[N03AG06, tiagabine, The metabolism of Tiagabine can be decreased when combined with Efavirenz.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be decreased when combined with Efavirenz.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Efavirenz.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Efavirenz.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Efavirenz is combined with Normethadone.]
[N06AB10, escitalopram, The metabolism of Escitalopram can be decreased when combined with Efavirenz.]
[G04BD08, solifenacin, The metabolism of Solifenacin can be decreased when combined with Efavirenz.]
[N06AA01, desipramine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[C09XA02, aliskiren, The metabolism of Aliskiren can be decreased when combined with Efavirenz.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Efavirenz.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Dexamethasone can be decreased when combined with Efavirenz.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Efavirenz is combined with Oxiracetam.]
[N04AA08, dexetimide, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, The metabolism of Oxybutynin can be decreased when combined with Efavirenz.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Efavirenz.]
[A03AA01, oxyphencyclimine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Efavirenz can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Efavirenz.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Efavirenz.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Efavirenz.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Efavirenz is combined with Dextromoramide.]
[N06AB05, paroxetine, The metabolism of Paroxetine can be decreased when combined with Efavirenz.]
[B01AC04, clopidogrel, The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Efavirenz resulting in a loss in efficacy.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Efavirenz is combined with Diamorphine.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Efavirenz.]
[N05BA01, diazepam, The metabolism of Diazepam can be decreased when combined with Efavirenz.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Efavirenz is combined with Phenacemide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Efavirenz is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Efavirenz is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Efavirenz.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Efavirenz.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Efavirenz.]
[A03AA07, dicyclomine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[C02DG01, pinacidil, The metabolism of Pinacidil can be decreased when combined with Efavirenz.]
[A03AX04, pinaverium, The serum concentration of Pinaverium can be decreased when it is combined with Efavirenz.]
[A10BG03, pioglitazone, The metabolism of Pioglitazone can be decreased when combined with Efavirenz.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Efavirenz is combined with Pipamperone.]
[A03AB14, pipenzolate, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Efavirenz.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Efavirenz.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Efavirenz is combined with Diethylpropion.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be decreased when combined with Efavirenz.]
[C08CA03, isradipine, The serum concentration of Isradipine can be decreased when it is combined with Efavirenz.]
[D07XC04, diflucortolone, The metabolism of Difluocortolone can be decreased when combined with Efavirenz.]
[A03AB11, poldine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Efavirenz.]
[C01AA05, digoxin, Digoxin may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[C02DB01, dihydralazine, The metabolism of Dihydralazine can be decreased when combined with Efavirenz.]
[C10AX09, ezetimibe, The metabolism of Ezetimibe can be increased when combined with Efavirenz.]
[C04AE04, dihydroergocristine, The serum concentration of Dihydroergocristine can be increased when it is combined with Efavirenz.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Efavirenz.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Efavirenz.]
[J05AE08, atazanavir, The serum concentration of Atazanavir can be decreased when it is combined with Efavirenz.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be decreased when combined with Efavirenz.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Pramocaine.]
[C08DB01, diltiazem, The serum concentration of Diltiazem can be decreased when it is combined with Efavirenz.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Efavirenz is combined with Pridinol.]
[R06AB03, dimethindene, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Efavirenz is combined with Progabide.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Efavirenz.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Efavirenz.]
[R06AA02, diphenhydramine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Efavirenz is combined with Diphenoxylate.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Efavirenz.]
[B01AC07, dipyridamole, Efavirenz may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Efavirenz is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Quinupramine.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Efavirenz.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Efavirenz.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Efavirenz.]
[C01BA03, disopyramide, The metabolism of Disopyramide can be decreased when combined with Efavirenz.]
[P03AA04, disulfiram, The metabolism of Disulfiram can be decreased when combined with Efavirenz.]
[S02AA12, rifamycin SV, The metabolism of Efavirenz can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Rifapentine can be decreased when combined with Efavirenz.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Efavirenz is combined with Riluzole.]
[N05AX08, risperidone, The metabolism of Risperidone can be decreased when combined with Efavirenz.]
[R06AE09, levocetirizine, The metabolism of Levocetirizine can be decreased when combined with Efavirenz.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Efavirenz.]
[J01MB01, rosoxacin, The metabolism of Efavirenz can be decreased when combined with Rosoxacin.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Efavirenz.]
[A04AD12, aprepitant, The metabolism of Aprepitant can be decreased when combined with Efavirenz.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Efavirenz.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Efavirenz.]
[J05AE07, fosamprenavir, The serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Efavirenz resulting in a loss in efficacy.]
[G04BE08, tadalafil, The serum concentration of Tadalafil can be increased when it is combined with Efavirenz.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Efavirenz.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be decreased when combined with Efavirenz.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be decreased when combined with Efavirenz.]
[R03AC12, salmeterol, The metabolism of Salmeterol can be decreased when combined with Efavirenz.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Efavirenz.]
[C01CA04, dopamine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Dopamine.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Efavirenz.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Efavirenz.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Efavirenz.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.]
[N06AB06, sertraline, The serum concentration of Sertraline can be decreased when it is combined with Efavirenz.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Efavirenz is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.]
[A08AA10, sibutramine, The metabolism of Sibutramine can be decreased when combined with Efavirenz.]
[C10AA01, simvastatin, The serum concentration of Simvastatin can be decreased when it is combined with Efavirenz.]
[G03DB01, dydrogesterone, The metabolism of Dydrogesterone can be decreased when combined with Efavirenz.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Efavirenz is combined with Sumatriptan.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Efavirenz.]
[H01AA01, corticotropin, The metabolism of Corticotropin can be decreased when combined with Efavirenz.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Temafloxacin.]
[M01AC02, tenoxicam, The metabolism of Tenoxicam can be decreased when combined with Efavirenz.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Efavirenz.]
[G04BD05, terodiline, The serum concentration of Terodiline can be decreased when it is combined with Efavirenz.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Efavirenz is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Efavirenz is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Efavirenz is combined with Thiopropazate.]
[G04BD01, emepronium, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Efavirenz.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Efavirenz is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The metabolism of Tolfenamic acid can be decreased when combined with Efavirenz.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Efavirenz is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Efavirenz.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Efavirenz.]
[L02BA02, toremifene, The metabolism of Toremifene can be decreased when combined with Efavirenz.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Efavirenz.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Efavirenz is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Efavirenz is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Efavirenz is combined with Triclofos.]
[A03AB08, tridihexethyl, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[H02CA01, trilostane, The metabolism of Trilostane can be decreased when combined with Efavirenz.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Efavirenz is combined with Trimethobenzamide.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Efavirenz.]
[N04AA12, tropatepine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Efavirenz.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Efavirenz is combined with Urapidil.]
[J01MA04, enoxacin, The metabolism of Efavirenz can be decreased when combined with Enoxacin.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Efavirenz is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Efavirenz.]
[S01GX10, epinastine, The metabolism of Epinastine can be decreased when combined with Efavirenz.]
[N06AX16, venlafaxine, The metabolism of Venlafaxine can be decreased when combined with Efavirenz.]
[S01GA03, xylometazoline, The serum concentration of Xylometazoline can be decreased when it is combined with Efavirenz.]
[C08CA12, mepirodipine, The metabolism of Barnidipine can be decreased when combined with Efavirenz.]
[S01EA01, epinephrine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Epinephrine.]
[N05CF02, zolpidem, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The metabolism of Zomepirac can be decreased when combined with Efavirenz.]
[N03AX15, zonisamide, The serum concentration of Zonisamide can be decreased when it is combined with Efavirenz.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Efavirenz.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Efavirenz.]
[C02AC02, guanfacine, The metabolism of Guanfacine can be decreased when combined with Efavirenz.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Moricizine.]
[G02AB03, ergonovine, The serum concentration of Ergometrine can be increased when it is combined with Efavirenz.]
[C04AE01, ergoloid mesylates, USP, The serum concentration of Ergoloid mesylate can be increased when it is combined with Efavirenz.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be decreased when combined with Efavirenz.]
[S01AA17, erythromycin, The metabolism of Erythromycin can be decreased when combined with Efavirenz.]
[N05CD04, estazolam, The metabolism of Estazolam can be decreased when combined with Efavirenz.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Efavirenz.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be decreased when combined with Efavirenz.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Efavirenz.]
[L01XX11, estramustine, The metabolism of Estramustine can be decreased when combined with Efavirenz.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Conjugated estrogens can be decreased when combined with Efavirenz.]
[J04AK02, ethambutol, The metabolism of Efavirenz can be decreased when combined with Ethambutol.]
[R03BA05, fluticasone, The metabolism of Fluticasone can be increased when combined with Efavirenz.]
[R03BA09, fluticasone furoate, The metabolism of Fluticasone furoate can be decreased when combined with Efavirenz.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Efavirenz.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Efavirenz.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Efavirenz.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Ibutilide.]
[N04AA05, profenamine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The serum concentration of Ethosuximide can be decreased when it is combined with Efavirenz.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Efavirenz is combined with Ethotoin.]
[M01AC06, meloxicam, The metabolism of Meloxicam can be decreased when combined with Efavirenz.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Efavirenz.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Efavirenz.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Efavirenz.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Efavirenz.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Efavirenz.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Efavirenz.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Efavirenz.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Efavirenz.]
[R06AX12, terfenadine, The metabolism of Efavirenz can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Bupropion can be increased when combined with Efavirenz.]
[N06AB08, fluvoxamine, The metabolism of Fluvoxamine can be decreased when combined with Efavirenz.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Efavirenz.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Efavirenz.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Efavirenz.]
[C10AA03, pravastatin, The serum concentration of Pravastatin can be decreased when it is combined with Efavirenz.]
[A05AA01, chenodeoxycholic acid, The metabolism of Chenodeoxycholic acid can be decreased when combined with Efavirenz.]
[D11AX24, deoxycholic acid, Deoxycholic acid may increase the excretion rate of Efavirenz which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Efavirenz.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Efavirenz.]
[C08CA02, felodipine, The serum concentration of Felodipine can be decreased when it is combined with Efavirenz.]
[C08EA01, fendiline, The serum concentration of Fendiline can be decreased when it is combined with Efavirenz.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Efavirenz.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Efavirenz.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Efavirenz.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Efavirenz.]
[G04BD02, flavoxate, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Flecainide.]
[J01CF05, floxacillin, Flucloxacillin may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[J02AC01, fluconazole, The metabolism of Efavirenz can be decreased when combined with Fluconazole.]
[H02AA02, fludrocortisone, The metabolism of Fludrocortisone can be decreased when combined with Efavirenz.]
[D07XB01, flumethasone, The metabolism of Flumethasone can be decreased when combined with Efavirenz.]
[N07CA03, flunarizine, The serum concentration of Flunarizine can be decreased when it is combined with Efavirenz.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Efavirenz.]
[D07AC08, fluocinonide, The metabolism of Fluocinonide can be decreased when combined with Efavirenz.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Efavirenz is combined with Melitracen.]
[H02AB03, fluocortolone, The metabolism of Fluocortolone can be decreased when combined with Efavirenz.]
[V03AZ01, ethanol, The risk or severity of adverse effects can be increased when Efavirenz is combined with Ethanol.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Efavirenz.]
[N06AB03, fluoxetine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Efavirenz.]
[N05CD01, flurazepam, The metabolism of Flurazepam can be decreased when combined with Efavirenz.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be increased when combined with Efavirenz.]
[N05AG01, fluspirilene, The serum concentration of Fluspirilene can be decreased when it is combined with Efavirenz.]
[L02BB01, flutamide, The metabolism of Flutamide can be decreased when combined with Efavirenz.]
[L01BC03, tegafur, The metabolism of Tegafur can be increased when combined with Efavirenz.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Efavirenz is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Efavirenz.]
[J05AE10, darunavir, The serum concentration of Efavirenz can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, The metabolism of Furosemide can be increased when combined with Efavirenz.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Efavirenz is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Amisulpride.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Efavirenz.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Gallamine.]
[C08DA02, gallopamil, The serum concentration of Gallopamil can be decreased when it is combined with Efavirenz.]
[S01AD09, ganciclovir, The risk or severity of adverse effects can be increased when Efavirenz is combined with Ganciclovir.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Efavirenz is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Efavirenz is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Gemfibrozil can be decreased when combined with Efavirenz.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Efavirenz.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Efavirenz.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Efavirenz.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Efavirenz.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Efavirenz.]
[N03AD03, methsuximide, The serum concentration of Methsuximide can be decreased when it is combined with Efavirenz.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be decreased when combined with Efavirenz.]
[N01AH02, alfentanil, The metabolism of Alfentanil can be decreased when combined with Efavirenz.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Efavirenz.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Efavirenz.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Efavirenz.]
[A10BB07, glipizide, The metabolism of Glipizide can be increased when combined with Efavirenz.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Efavirenz is combined with Glutethimide.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Efavirenz.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Efavirenz.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Efavirenz.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Efavirenz.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Efavirenz.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Efavirenz.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Efavirenz.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Efavirenz is combined with Halothane.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Efavirenz.]
[N05AH04, quetiapine, The serum concentration of Quetiapine can be increased when it is combined with Efavirenz.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Efavirenz is combined with Iprazochrome.]
[L01CE02, irinotecan, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Efavirenz.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Efavirenz is combined with Allobarbital.]
[C09CA01, losartan, The metabolism of Losartan can be decreased when combined with Efavirenz.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Efavirenz.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Efavirenz is combined with Hexobarbital.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Efavirenz.]
[C08CA10, nilvadipine, The serum concentration of Nilvadipine can be decreased when it is combined with Efavirenz.]
[M02AA26, nimesulide, The serum concentration of Nimesulide can be decreased when it is combined with Efavirenz.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Efavirenz.]
[R05DA03, hydrocodone, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Hydrocortisone can be decreased when combined with Efavirenz.]
[G04BD06, propiverine, The metabolism of Propiverine can be decreased when combined with Efavirenz.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Efavirenz.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Efavirenz is combined with Prothipendyl.]
[G03DA03, 17-alpha-hydroxyprogesterone, The metabolism of Hydroxyprogesterone can be decreased when combined with Efavirenz.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Rifabutin can be increased when combined with Efavirenz.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Efavirenz.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Efavirenz.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Efavirenz.]
[H01AC02, somatrem, The metabolism of Efavirenz can be increased when combined with Somatrem.]
[N01AH03, sufentanil, The metabolism of Sufentanil can be decreased when combined with Efavirenz.]
[N06AA02, imipramine, The metabolism of Imipramine can be decreased when combined with Efavirenz.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Efavirenz.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Terlipressin.]
[M03BX02, tizanidine, The metabolism of Tizanidine can be decreased when combined with Efavirenz.]
[C03BA11, indapamide, The metabolism of Indapamide can be decreased when combined with Efavirenz.]
[S01BC01, indomethacin, The metabolism of Indomethacin can be increased when combined with Efavirenz.]
[L03AB04, interferon alfa-2a, The metabolism of Efavirenz can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Efavirenz can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be decreased when combined with Efavirenz.]
[A03AA30, piperidolate, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Articaine.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Efavirenz.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Efavirenz.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Efavirenz.]
[R06AE01, buclizine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Efavirenz.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Efavirenz is combined with Alprenolol.]
[L03AB09, interferon alfacon-1, The metabolism of Efavirenz can be decreased when combined with Interferon alfacon-1.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Efavirenz.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Efavirenz is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Efavirenz is combined with Iproniazid.]
[J05AB13, penciclovir, The metabolism of Penciclovir can be decreased when combined with Efavirenz.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Efavirenz is combined with Isocarboxazid.]
[P01AX06, atovaquone, The serum concentration of Atovaquone can be decreased when it is combined with Efavirenz.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Efavirenz is combined with Isoflurane.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Efavirenz.]
[J04AC01, isoniazid, The metabolism of Efavirenz can be decreased when combined with Isoniazid.]
[D10BA01, isotretinoin, The metabolism of Isotretinoin can be decreased when combined with Efavirenz.]
[P02CF01, ivermectin, The metabolism of Ivermectin can be decreased when combined with Efavirenz.]
[N06AX18, reboxetine, The metabolism of Reboxetine can be decreased when combined with Efavirenz.]
[H01AC01, somatropin, The metabolism of Efavirenz can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Efavirenz can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Efavirenz.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Efavirenz is combined with Ketanserin.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Efavirenz.]
[J02AB02, ketoconazole, The metabolism of Ketoconazole can be decreased when combined with Efavirenz.]
[H02CA04, levoketoconazole, The metabolism of Levoketoconazole can be decreased when combined with Efavirenz.]
[N05AH03, olanzapine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[M02AA10, ketoprofen, The metabolism of Ketoprofen can be increased when combined with Efavirenz.]
[V03AC03, deferasirox, The metabolism of Deferasirox can be increased when combined with Efavirenz.]
[L04AA24, abatacept, The metabolism of Efavirenz can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Mizolastine.]
[N04BC09, rotigotine, Efavirenz may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Nalidixic acid.]
[C07AG01, labetalol, The metabolism of Labetalol can be increased when combined with Efavirenz.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Amantadine.]
[J05AX09, maraviroc, The serum concentration of Maraviroc can be decreased when it is combined with Efavirenz.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Efavirenz.]
[R05CB06, ambroxol, The metabolism of Ambroxol can be decreased when combined with Efavirenz.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be decreased when combined with Efavirenz.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Efavirenz is combined with Levodopa.]
[S02DA01, lidocaine, The metabolism of Lidocaine can be decreased when combined with Efavirenz.]
[C08EX01, lidoflazine, The serum concentration of Lidoflazine can be decreased when it is combined with Efavirenz.]
[N06BA13, armodafinil, The metabolism of Efavirenz can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Efavirenz.]
[N02CA07, lisuride, The serum concentration of Lisuride can be increased when it is combined with Efavirenz.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Lofepramine.]
[A07DA03, loperamide, The serum concentration of Loperamide can be decreased when it is combined with Efavirenz.]
[N05BA06, lorazepam, The metabolism of Lorazepam can be decreased when combined with Efavirenz.]
[C10AA02, lovastatin, The serum concentration of Lovastatin can be decreased when it is combined with Efavirenz.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Efavirenz.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Efavirenz.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Efavirenz.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Efavirenz can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Nilotinib can be decreased when combined with Efavirenz.]
[N06AA21, maprotiline, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Efavirenz.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Meclizine.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Efavirenz is combined with Medazepam.]
[G03DB03, medrogestone, The metabolism of Medrogestone can be decreased when combined with Efavirenz.]
[P01BC02, mefloquine, The metabolism of Mefloquine can be decreased when combined with Efavirenz.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Efavirenz is combined with Melatonin.]
[N06DX01, memantine, The metabolism of Efavirenz can be decreased when combined with Memantine.]
[N02AB02, meperidine, The metabolism of Meperidine can be decreased when combined with Efavirenz.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Efavirenz.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Efavirenz is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Efavirenz.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Efavirenz is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Mesoridazine.]
[N05AX13, paliperidone, The metabolism of Paliperidone can be decreased when combined with Efavirenz.]
[A04AA04, dolasetron, The metabolism of Dolasetron can be decreased when combined with Efavirenz.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Efavirenz.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Metamfetamine.]
[A03AB07, methantheline, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Efavirenz is combined with Methapyrilene.]
[N05CM01, methaqualone, The metabolism of Methaqualone can be decreased when combined with Efavirenz.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Efavirenz.]
[G02CB05, metergoline, The serum concentration of Metergoline can be increased when it is combined with Efavirenz.]
[H03BB02, methimazole, The metabolism of Efavirenz can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The metabolism of Pemetrexed can be decreased when combined with Efavirenz.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Efavirenz.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Efavirenz.]
[N02BG08, ziconotide, The serum concentration of Ziconotide can be decreased when it is combined with Efavirenz.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Efavirenz.]
[N05AA02, methotrimeprazine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[D05BA02, methoxsalen, The metabolism of Efavirenz can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Efavirenz is combined with Methoxyflurane.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Efavirenz is combined with Methylene blue.]
[G02AB01, methylergonovine, The serum concentration of Methylergometrine can be increased when it is combined with Efavirenz.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Efavirenz.]
[H02AB04, methylprednisolone, The metabolism of Methylprednisolone can be decreased when combined with Efavirenz.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Efavirenz.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be decreased when combined with Efavirenz.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Efavirenz is combined with Methyprylon.]
[N02CA04, methysergide, The serum concentration of Methysergide can be increased when it is combined with Efavirenz.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Efavirenz.]
[P01AB01, metronidazole, The metabolism of Metronidazole can be increased when combined with Efavirenz.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Efavirenz.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Efavirenz.]
[S02AA13, miconazole, The metabolism of Efavirenz can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Efavirenz.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Efavirenz.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be decreased when combined with Efavirenz.]
[C09CA03, valsartan, The metabolism of Valsartan can be decreased when combined with Efavirenz.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.]
[D11AX01, minoxidil, The metabolism of Minoxidil can be increased when combined with Efavirenz.]
[L01XX23, mitotane, The metabolism of Efavirenz can be increased when combined with Mitotane.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Efavirenz is combined with Molindone.]
[C01BD01, amiodarone, The serum concentration of Amiodarone can be decreased when it is combined with Efavirenz.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Efavirenz.]
[N02AA01, morphine, The metabolism of Morphine can be decreased when combined with Efavirenz.]
[A04AA05, palonosetron, The metabolism of Palonosetron can be decreased when combined with Efavirenz.]
[L04AB05, certolizumab pegol, The metabolism of Efavirenz can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be increased when combined with Efavirenz.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Efavirenz.]
[L04AA06, mycophenolic acid, The metabolism of Mycophenolic acid can be increased when combined with Efavirenz.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Efavirenz is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Efavirenz is combined with Amobarbital.]
[J05AJ01, raltegravir, The metabolism of Raltegravir can be increased when combined with Efavirenz.]
[P01BA06, amodiaquine, Efavirenz may increase the hepatotoxic activities of Amodiaquine.]
[G04CA04, silodosin, The metabolism of Silodosin can be decreased when combined with Efavirenz.]
[R03BB01, ipratropium bromide, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G03XC01, raloxifene, The metabolism of Efavirenz can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The serum concentration of Efavirenz can be decreased when it is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The metabolism of Efavirenz can be decreased when combined with Interferon beta-1b.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Efavirenz is combined with Ropinirole.]
[J01CF06, nafcillin, The metabolism of Efavirenz can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Efavirenz is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Efavirenz can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The metabolism of Naltrexone can be increased when combined with Efavirenz.]
[L04AC03, anakinra, The metabolism of Efavirenz can be increased when combined with Anakinra.]
[M02AA12, naproxen, The metabolism of Naproxen can be increased when combined with Efavirenz.]
[A10BG01, troglitazone, Troglitazone may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Efavirenz.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Efavirenz.]
[L02BG04, letrozole, The metabolism of Letrozole can be decreased when combined with Efavirenz.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Efavirenz is combined with Remifentanil.]
[A10BX02, repaglinide, The metabolism of Repaglinide can be decreased when combined with Efavirenz.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Levosimendan.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Efavirenz.]
[N06AX23, desvenlafaxine, The metabolism of Desvenlafaxine can be decreased when combined with Efavirenz.]
[C09CA07, telmisartan, Efavirenz may decrease the excretion rate of Telmisartan which could result in a higher serum level.]
[M04AA03, febuxostat, The metabolism of Febuxostat can be increased when combined with Efavirenz.]
[H05BX02, paricalcitol, The metabolism of Paricalcitol can be decreased when combined with Efavirenz.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Efavirenz is combined with Nialamide.]
[C08CA04, nicardipine, The serum concentration of Nicardipine can be decreased when it is combined with Efavirenz.]
[C04AE02, nicergoline, The serum concentration of Nicergoline can be increased when it is combined with Efavirenz.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Efavirenz.]
[N07BA01, nicotine, The metabolism of Efavirenz can be decreased when combined with Nicotine.]
[C08CA05, nifedipine, The serum concentration of Nifedipine can be decreased when it is combined with Efavirenz.]
[C08CA06, nimodipine, The serum concentration of Nimodipine can be decreased when it is combined with Efavirenz.]
[C08CA07, nisoldipine, The serum concentration of Nisoldipine can be decreased when it is combined with Efavirenz.]
[N05CD02, nitrazepam, The metabolism of Nitrazepam can be decreased when combined with Efavirenz.]
[C08CA08, nitrendipine, The serum concentration of Nitrendipine can be decreased when it is combined with Efavirenz.]
[J01XE01, nitrofurantoin, Efavirenz may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The metabolism of Zaleplon can be decreased when combined with Efavirenz.]
[N04BC05, pramipexole, Efavirenz may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Efavirenz is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Nomifensine.]
[C01CA03, norepinephrine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Norepinephrine.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Efavirenz.]
[S01AE02, norfloxacin, The metabolism of Efavirenz can be decreased when combined with Norfloxacin.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Efavirenz.]
[C02KX01, bosentan, The metabolism of Bosentan can be decreased when combined with Efavirenz.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Efavirenz.]
[L03AB07, interferon beta-1a, The metabolism of Efavirenz can be decreased when combined with Interferon beta-1a.]
[G02CA02, nylidrin, The serum concentration of Nylidrin can be decreased when it is combined with Efavirenz.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Efavirenz.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Efavirenz can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Efavirenz.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Efavirenz is combined with Opipramol.]
[N02AA02, opium, The metabolism of Opium can be decreased when combined with Efavirenz.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Efavirenz.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Efavirenz is combined with Oxazepam.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Efavirenz.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Efavirenz is combined with Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be decreased when combined with Efavirenz.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be decreased when combined with Efavirenz.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Oxypertine.]
[A03AB03, oxyphenonium, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Efavirenz.]
[N05AH05, asenapine, The metabolism of Asenapine can be decreased when combined with Efavirenz.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.]
[M03AC01, pancuronium, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be decreased when combined with Efavirenz.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Papaverine.]
[N05CC05, paraldehyde, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[H02AB05, paramethasone, The metabolism of Paramethasone can be decreased when combined with Efavirenz.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Efavirenz is combined with Pargyline.]
[J01MA03, pefloxacin, The metabolism of Efavirenz can be decreased when combined with Pefloxacin.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Efavirenz.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Efavirenz is combined with Penbutolol.]
[N05AG03, penfluridol, The serum concentration of Penfluridol can be decreased when it is combined with Efavirenz.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Pentazocine.]
[N05CA01, pentobarbital, The metabolism of Efavirenz can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, The metabolism of Pentoxifylline can be decreased when combined with Efavirenz.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Perazine.]
[N04BC02, pergolide, The serum concentration of Pergolide can be increased when it is combined with Efavirenz.]
[C08EX02, perhexiline, The serum concentration of Perhexiline can be decreased when it is combined with Efavirenz.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Efavirenz.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Phenelzine.]
[A10BA01, phenformin, The risk or severity of adverse effects can be increased when Efavirenz is combined with Phenformin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Efavirenz.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be decreased when combined with Efavirenz.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Phenoperidine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Efavirenz.]
[A08AA01, phentermine, The metabolism of Phentermine can be decreased when combined with Efavirenz.]
[M02AA01, phenylbutazone, The metabolism of Phenylbutazone can be decreased when combined with Efavirenz.]
[S01GA05, phenylephrine, The metabolism of Efavirenz can be increased when combined with Phenylephrine.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Efavirenz.]
[N03AB02, phenytoin, The serum concentration of Efavirenz can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Efavirenz can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Efavirenz.]
[C08CX01, mibefradil, The serum concentration of Mibefradil can be decreased when it is combined with Efavirenz.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Efavirenz.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Efavirenz is combined with Pindolol.]
[C10AA05, atorvastatin, The serum concentration of Atorvastatin can be decreased when it is combined with Efavirenz.]
[J05AE01, saquinavir, Saquinavir may increase the hepatotoxic activities of Efavirenz.]
[N05AC04, pipothiazine, The metabolism of Pipotiazine can be decreased when combined with Efavirenz.]
[A02BX03, pirenzepine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Efavirenz is combined with Piritramide.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Efavirenz.]
[J01MA11, grepafloxacin, The metabolism of Grepafloxacin can be decreased when combined with Efavirenz.]
[N02CX01, pizotyline, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Delavirdine can be decreased when combined with Efavirenz.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Efavirenz.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Efavirenz is combined with Proxibarbal.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be decreased when combined with Efavirenz.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Efavirenz.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Efavirenz.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Efavirenz.]
[L04AC08, canakinumab, The metabolism of Efavirenz can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The risk or severity of adverse effects can be increased when Efavirenz is combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be decreased when combined with Efavirenz.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Efavirenz.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Efavirenz.]
[N05BA11, prazepam, The metabolism of Prazepam can be decreased when combined with Efavirenz.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Efavirenz.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Efavirenz is combined with Prazosin.]
[S03BA02, prednisolone, The metabolism of Prednisolone can be decreased when combined with Efavirenz.]
[H02AB07, prednisone, The metabolism of Prednisone can be decreased when combined with Efavirenz.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Antazoline.]
[C01DX02, prenylamine, The serum concentration of Prenylamine can be decreased when it is combined with Efavirenz.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Primaquine can be decreased when combined with Efavirenz.]
[N03AA03, primidone, The metabolism of Efavirenz can be increased when combined with Primidone.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Procarbazine.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be decreased when combined with Efavirenz.]
[N05AB04, prochlorperazine, The metabolism of Prochlorperazine can be decreased when combined with Efavirenz.]
[N04AA04, procyclidine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Efavirenz.]
[N05AA03, promazine, The metabolism of Promazine can be decreased when combined with Efavirenz.]
[G03DB07, promegestone, The metabolism of Promegestone can be decreased when combined with Efavirenz.]
[R06AD02, promethazine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The metabolism of Propafenone can be decreased when combined with Efavirenz.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Efavirenz is combined with Propanidid.]
[A03AB05, propantheline, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Periciazine.]
[N05CM06, propiomazine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Efavirenz.]
[N01AX10, propofol, The metabolism of Propofol can be increased when combined with Efavirenz.]
[N02AC04, propoxyphene, The metabolism of Dextropropoxyphene can be decreased when combined with Efavirenz.]
[C07AA05, propranolol, The serum concentration of Propranolol can be decreased when it is combined with Efavirenz.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Efavirenz is combined with Rizatriptan.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Efavirenz.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Efavirenz.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Efavirenz.]
[A03AB15, diphemanil, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Efavirenz.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Efavirenz is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Efavirenz is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Efavirenz is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Efavirenz is combined with Mepyramine.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Efavirenz.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Efavirenz.]
[P01BC01, quinine, The metabolism of Quinine can be decreased when combined with Efavirenz.]
[A02BA02, ranitidine, The metabolism of Ranitidine can be decreased when combined with Efavirenz.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Efavirenz can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Efavirenz is combined with Oxitriptan.]
[J01FA06, roxithromycin, The metabolism of Roxithromycin can be decreased when combined with Efavirenz.]
[S01BC08, salicylic acid, The metabolism of Salicylic acid can be decreased when combined with Efavirenz.]
[S01FA02, scopolamine, The metabolism of Scopolamine can be decreased when combined with Efavirenz.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Efavirenz.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Efavirenz.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Sotalol.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Efavirenz.]
[C03DA01, spironolactone, Spironolactone may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Efavirenz.]
[N03AG01, valproic acid, The metabolism of Valproic acid can be increased when combined with Efavirenz.]
[D07AB02, hydrocortisone butyrate, The metabolism of Hydrocortisone butyrate can be decreased when combined with Efavirenz.]
[A05AA02, ursodiol, Ursodeoxycholic acid may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Emtricitabine which could result in a higher serum level.]
[C08DA01, verapamil, The excretion of Emtricitabine can be decreased when combined with Verapamil.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Emtricitabine.]
[L01ED04, brigatinib, The excretion of Emtricitabine can be decreased when combined with Brigatinib.]
[L01EF03, abemaciclib, The excretion of Abemaciclib can be decreased when combined with Emtricitabine.]
[J01GB14, plazomicin, The excretion of Emtricitabine can be decreased when combined with Plazomicin.]
[P01BA07, tafenoquine, The excretion of Emtricitabine can be decreased when combined with Tafenoquine.]
[L01EX13, gilteritinib, The excretion of Emtricitabine can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The excretion of Emtricitabine can be decreased when combined with Glasdegib.]
[N06BA14, solriamfetol, The excretion of Solriamfetol can be decreased when combined with Emtricitabine.]
[L01EX15, pexidartinib, The excretion of Emtricitabine can be decreased when combined with Pexidartinib.]
[L01EJ02, fedratinib, The excretion of Emtricitabine can be decreased when combined with Fedratinib.]
[N04CX01, istradefylline, The excretion of Emtricitabine can be decreased when combined with Istradefylline.]
[J01DB01, cephalexin, The excretion of Emtricitabine can be decreased when combined with Cephalexin.]
[J01DB09, cephradine, The excretion of Cefradine can be decreased when combined with Emtricitabine.]
[L01XX72, tazemetostat, The excretion of Emtricitabine can be decreased when combined with Tazemetostat.]
[J05AB16, remdesivir, The excretion of Emtricitabine can be decreased when combined with Remdesivir.]
[L01EH03, tucatinib, The excretion of Emtricitabine can be decreased when combined with Tucatinib.]
[L01EX17, capmatinib, The excretion of Emtricitabine can be decreased when combined with Capmatinib.]
[L01EX19, ripretinib, The excretion of Emtricitabine can be decreased when combined with Ripretinib.]
[L01EX22, selpercatinib, The excretion of Emtricitabine can be decreased when combined with Selpercatinib.]
[M09AX10, risdiplam, The serum concentration of Emtricitabine can be increased when it is combined with Risdiplam.]
[L01EX23, pralsetinib, The excretion of Emtricitabine can be decreased when combined with Pralsetinib.]
[V03AF12, trilaciclib, The excretion of Emtricitabine can be decreased when combined with Trilaciclib.]
[A02BA01, cimetidine, The excretion of Emtricitabine can be decreased when combined with Cimetidine.]
[S03AA07, ciprofloxacin, The excretion of Emtricitabine can be decreased when combined with Ciprofloxacin.]
[P01CA03, fexinidazole, The excretion of Emtricitabine can be decreased when combined with Fexinidazole.]
[J05AB14, valganciclovir, The risk or severity of cytopenia can be increased when Valganciclovir is combined with Emtricitabine.]
[S01AD03, acyclovir, The excretion of Emtricitabine can be decreased when combined with Acyclovir.]
[N07BC04, lofexidine, The excretion of Emtricitabine can be decreased when combined with Lofexidine.]
[S02AA12, rifamycin SV, The excretion of Emtricitabine can be decreased when combined with Rifamycin.]
[C01EB18, ranolazine, The excretion of Emtricitabine can be decreased when combined with Ranolazine.]
[A02BA03, famotidine, The excretion of Emtricitabine can be decreased when combined with Famotidine.]
[C01BC04, flecainide, The excretion of Flecainide can be decreased when combined with Emtricitabine.]
[S01AD09, ganciclovir, The risk or severity of cytopenia can be increased when Ganciclovir is combined with Emtricitabine.]
[L01CE01, topotecan, The excretion of Topotecan can be decreased when combined with Emtricitabine.]
[A10BA02, metformin, The excretion of Emtricitabine can be decreased when combined with Metformin.]
[V04CG05, methylene blue, The excretion of Emtricitabine can be decreased when combined with Methylene blue.]
[C07AA12, nadolol, The excretion of Nadolol can be decreased when combined with Emtricitabine.]
[S01AE05, levofloxacin, The excretion of Levofloxacin can be decreased when combined with Emtricitabine.]
[C01BA02, procainamide, The excretion of Procainamide can be decreased when combined with Emtricitabine.]
[P01BD01, pyrimethamine, The excretion of Emtricitabine can be decreased when combined with Pyrimethamine.]
[J05AP01, ribavirin, Ribavirin may increase the hepatotoxic activities of Emtricitabine.]
[H02CA04, levoketoconazole, The excretion of Emtricitabine can be decreased when combined with Levoketoconazole.]
[S02DA03, antipyrine, Antipyrine may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01GA01, streptomycin, Streptomycin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[A02BX02, sucralfate, Tenofovir disoproxil may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Tenofovir disoproxil may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Tenofovir disoproxil may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, Tenofovir disoproxil may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M01AB02, sulindac, Sulindac may increase the nephrotoxic activities of Tenofovir disoproxil.]
[M01AX04, apazone, Azapropazone may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01BB02, mercaptopurine, The excretion of Tenofovir disoproxil can be decreased when combined with Mercaptopurine.]
[L02BA01, tamoxifen, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Tamoxifen.]
[N05CD07, temazepam, Tenofovir disoproxil may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[R03CC03, terbutaline, Tenofovir disoproxil may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Tenofovir disoproxil.]
[G03BA03, testosterone, The excretion of Tenofovir disoproxil can be increased when combined with Testosterone.]
[S03AA02, tetracycline, The excretion of Tenofovir disoproxil can be decreased when combined with Tetracycline.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may increase the nephrotoxic activities of Tenofovir disoproxil.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Tenofovir disoproxil may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[R06AD03, thiethylperazine, Tenofovir disoproxil may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[G04BE06, moxisylyte, Tenofovir disoproxil may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Tenofovir disoproxil may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Tenofovir disoproxil may decrease the excretion rate of Ticlopidine which could result in a higher serum level.]
[S01ED01, timolol, Tenofovir disoproxil may decrease the excretion rate of Timolol which could result in a higher serum level.]
[P01AB02, tinidazole, Tenofovir disoproxil may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Tobramycin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[A10BB05, tolazamide, Tenofovir disoproxil may decrease the excretion rate of Tolazamide which could result in a higher serum level.]
[V04CA01, tolbutamide, Tenofovir disoproxil may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, Tolmetin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N02AX02, tramadol, Tenofovir disoproxil may decrease the excretion rate of Tramadol which could result in a higher serum level.]
[C03DB02, triamterene, Triamterene may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N05CD05, triazolam, Tenofovir disoproxil may decrease the excretion rate of Triazolam which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX12, trientine, Tenofovir disoproxil may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, Tenofovir disoproxil may decrease the excretion rate of Trifluridine which could result in a higher serum level.]
[A03AA05, trimebutine, Tenofovir disoproxil may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01EA01, trimethoprim, Tenofovir disoproxil may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Tenofovir disoproxil.]
[R03DX07, roflumilast, Tenofovir disoproxil may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Tenofovir disoproxil may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Vandetanib.]
[R02AA14, oxyquinoline, Tenofovir disoproxil may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Linagliptin.]
[J05AP02, telaprevir, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Telaprevir.]
[S01AA28, vancomycin, Vancomycin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N03AX21, ezogabine, Tenofovir disoproxil may decrease the excretion rate of Ezogabine which could result in a higher serum level.]
[B01AF01, rivaroxaban, The serum concentration of Rivaroxaban can be increased when it is combined with Tenofovir disoproxil.]
[R03AC18, indacaterol, The serum concentration of Indacaterol can be increased when it is combined with Tenofovir disoproxil.]
[B01AC24, ticagrelor, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, Tenofovir disoproxil may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Tenofovir disoproxil.]
[L01CA02, vincristine, The serum concentration of Vincristine can be increased when it is combined with Tenofovir disoproxil.]
[B03BA01, vitamin B12, Tenofovir disoproxil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.]
[B01AA03, warfarin, Tenofovir disoproxil may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The excretion of Tenofovir disoproxil can be decreased when combined with Zidovudine.]
[L01EC01, vemurafenib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Tenofovir disoproxil.]
[M05BA05, tiludronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Tiludronic acid.]
[B06AC02, icatibant, Tenofovir disoproxil may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Crizotinib.]
[A02BC04, rabeprazole, Tenofovir disoproxil may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Ibandronate.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Tenofovir disoproxil may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, Acetylsalicylic acid may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01EJ01, ruxolitinib, Tenofovir disoproxil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Tenofovir disoproxil may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, Tenofovir disoproxil may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[M01CB03, auranofin, Tenofovir disoproxil may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Tenofovir disoproxil.]
[R07AX02, ivacaftor, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Ivacaftor.]
[B03XA04, peginesatide, Tenofovir disoproxil may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Tenofovir disoproxil may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Tenofovir disoproxil may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Tenofovir disoproxil.]
[J01DF01, aztreonam, Tenofovir disoproxil may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Tenofovir disoproxil.]
[M03BX01, baclofen, Tenofovir disoproxil may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Tenofovir disoproxil.]
[A08AA11, lorcaserin, Tenofovir disoproxil may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Carfilzomib.]
[L02BB04, enzalutamide, Tenofovir disoproxil may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Tenofovir disoproxil.]
[L04AA31, teriflunomide, The excretion of Tenofovir disoproxil can be decreased when combined with Teriflunomide.]
[L01EX05, regorafenib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Regorafenib.]
[D02BA02, octinoxate, Tenofovir disoproxil may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Tenofovir disoproxil.]
[N04BD02, rasagiline, Tenofovir disoproxil may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[V09IX04, fluorodeoxyglucose F18, Tenofovir disoproxil may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[G04BE03, sildenafil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Sildenafil.]
[V08CA11, gadofosveset, Tenofovir disoproxil may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Apixaban can be increased when it is combined with Tenofovir disoproxil.]
[A16AX08, teduglutide, Tenofovir disoproxil may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C10AX12, lomitapide, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Lomitapide.]
[A10BH04, alogliptin, Tenofovir disoproxil may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Tenofovir disoproxil may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Tenofovir disoproxil.]
[N02BA10, benorilate, Benorilate may increase the nephrotoxic activities of Tenofovir disoproxil.]
[A10BK02, canagliflozin, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Canagliflozin.]
[A06AX06, tegaserod, The serum concentration of Tegaserod can be increased when it is combined with Tenofovir disoproxil.]
[J02AX04, caspofungin, The excretion of Tenofovir disoproxil can be decreased when combined with Caspofungin.]
[L03AA12, ancestim, Tenofovir disoproxil may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L04AA18, everolimus, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, Tenofovir disoproxil may decrease the excretion rate of Benzatropine which could result in a higher serum level.]
[L01EC02, dabrafenib, The excretion of Tenofovir disoproxil can be decreased when combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01EE01, trametinib, Tenofovir disoproxil may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[V09AX05, florbetapir F-18, Tenofovir disoproxil may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[L01EB03, afatinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Afatinib.]
[N06AX28, levomilnacipran, Tenofovir disoproxil may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C02KX05, riociguat, The serum concentration of Riociguat can be increased when it is combined with Tenofovir disoproxil.]
[A10BJ03, lixisenatide, Tenofovir disoproxil may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[A05AA03, cholic acid, The excretion of Tenofovir disoproxil can be decreased when combined with Cholic Acid.]
[C02KX04, macitentan, Tenofovir disoproxil may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, Tenofovir disoproxil may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, Tenofovir disoproxil may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[J05AP05, simeprevir, The serum concentration of Simeprevir can be decreased when it is combined with Tenofovir disoproxil.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be increased when it is combined with Tenofovir disoproxil.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Tenofovir disoproxil may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, Tenofovir disoproxil may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Tenofovir disoproxil may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Tenofovir disoproxil may decrease the excretion rate of Formestane which could result in a higher serum level.]
[V03AB34, fomepizole, Tenofovir disoproxil may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Tenofovir disoproxil.]
[B01AC26, vorapaxar, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Vorapaxar.]
[L01XH04, belinostat, The serum concentration of Belinostat can be increased when it is combined with Tenofovir disoproxil.]
[L01EM01, idelalisib, The serum concentration of Idelalisib can be increased when it is combined with Tenofovir disoproxil.]
[N07XX08, tafamidis, The excretion of Tenofovir disoproxil can be decreased when combined with Tafamidis.]
[V08AA01, diatrizoic acid, Tenofovir disoproxil may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[V08AA04, iothalamic acid, Tenofovir disoproxil may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[N05CM19, suvorexant, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Eliglustat.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01EX09, nintedanib, The serum concentration of Nintedanib can be increased when it is combined with Tenofovir disoproxil.]
[S03AA06, gentamicin, Gentamicin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J05AP09, dasabuvir, The serum concentration of Dasabuvir can be increased when it is combined with Tenofovir disoproxil.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Tenofovir disoproxil.]
[L01EF01, palbociclib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The excretion of Tenofovir disoproxil can be decreased when combined with Lenvatinib.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Tenofovir disoproxil.]
[J05AP07, daclatasvir, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, Tenofovir disoproxil may decrease the excretion rate of Acetaminophen which could result in a higher serum level.]
[L01DC01, bleomycin, Tenofovir disoproxil may decrease the excretion rate of Bleomycin which could result in a higher serum level.]
[J05AF08, adefovir dipivoxil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Adefovir dipivoxil.]
[J05AP06, asunaprevir, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Asunaprevir.]
[A04AD14, rolapitant, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Flibanserin.]
[M02AA25, aceclofenac, Aceclofenac may increase the nephrotoxic activities of Tenofovir disoproxil.]
[M01AB11, acemetacin, Acemetacin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC03, lansoprazole, The excretion of Tenofovir disoproxil can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Tenofovir disoproxil may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J02AC05, isavuconazole, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Tenofovir disoproxil.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tenofovir disoproxil.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Tenofovir disoproxil.]
[L01XG03, ixazomib, Tenofovir disoproxil may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, The serum concentration of Selexipag can be increased when it is combined with Tenofovir disoproxil.]
[M04AB05, lesinurad, Tenofovir disoproxil may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[J05AP10, elbasvir, The serum concentration of Elbasvir can be increased when it is combined with Tenofovir disoproxil.]
[J05AP11, grazoprevir, The serum concentration of Grazoprevir can be increased when it is combined with Tenofovir disoproxil.]
[M01AE16, alminoprofen, Alminoprofen may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N03AX23, brivaracetam, Tenofovir disoproxil may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[L01XX52, venetoclax, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Venetoclax.]
[N05BA08, bromazepam, Tenofovir disoproxil may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[A02AD05, aluminum magnesium silicate, Tenofovir disoproxil may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[C03CA02, bumetanide, Bumetanide may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N01BB01, bupivacaine, Tenofovir disoproxil may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N05BE01, buspirone, Tenofovir disoproxil may decrease the excretion rate of Buspirone which could result in a higher serum level.]
[L01XX27, arsenic trioxide, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Arsenic trioxide.]
[M02AA03, clofezone, Tenofovir disoproxil may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[A07EC04, balsalazide, Balsalazide may increase the nephrotoxic activities of Tenofovir disoproxil.]
[A06AH05, naldemedine, Tenofovir disoproxil may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Tenofovir disoproxil may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Tenofovir disoproxil may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[P01CA02, benznidazole, Tenofovir disoproxil may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The excretion of Tenofovir disoproxil can be decreased when combined with Linezolid.]
[J05AF06, abacavir, Tenofovir disoproxil may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The serum concentration of Tipranavir can be decreased when it is combined with Tenofovir disoproxil.]
[N07XX13, valbenazine, Tenofovir disoproxil may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[J01MA23, delafloxacin, Tenofovir disoproxil may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Tenofovir disoproxil.]
[L01BC06, capecitabine, Tenofovir disoproxil may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XX59, enasidenib, The excretion of Tenofovir disoproxil can be decreased when combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tenofovir disoproxil.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Tenofovir disoproxil.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Tenofovir disoproxil.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Tenofovir disoproxil.]
[J01DC10, cefprozil, Cefprozil may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Tenofovir disoproxil may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[M01AB07, bumadizone, Bumadizone may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J05AX18, letermovir, The excretion of Tenofovir disoproxil can be decreased when combined with Letermovir.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, Tenofovir disoproxil may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The excretion of Tenofovir disoproxil can be decreased when combined with Captopril.]
[L02BB05, apalutamide, The serum concentration of Tenofovir disoproxil can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Tenofovir disoproxil can be decreased when it is combined with Carbamazepine.]
[J01CA03, carbenicillin, The excretion of Tenofovir disoproxil can be decreased when combined with Carbenicillin.]
[C07AG02, carvedilol, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Carvedilol.]
[B02BX08, avatrombopag, The excretion of Tenofovir disoproxil can be decreased when combined with Avatrombopag.]
[L04AA37, baricitinib, Tenofovir disoproxil may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DD10, cefetamet, Cefetamet may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DD09, cefodizime, Cefodizime may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DC11, ceforanide, Ceforanide may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DD13, cefpodoxime, Cefpodoxime may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Tenofovir disoproxil.]
[J01DD14, ceftibuten, Ceftibuten may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01GB14, plazomicin, Plazomicin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[H01CC03, elagolix, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Elagolix.]
[A16AX14, migalastat, Tenofovir disoproxil may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The excretion of Tenofovir disoproxil can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Tenofovir disoproxil.]
[L01EM04, duvelisib, The serum concentration of Duvelisib can be increased when it is combined with Tenofovir disoproxil.]
[L01EB07, dacomitinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Tenofovir disoproxil.]
[S01GX12, cetirizine, Tenofovir disoproxil may decrease the excretion rate of Cetirizine which could result in a higher serum level.]
[D08AE05, chloroxylenol, Tenofovir disoproxil may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, Lornoxicam may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N07XX15, inotersen, Inotersen may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Tenofovir disoproxil.]
[R03BB08, revefenacin, The serum concentration of Revefenacin can be increased when it is combined with Tenofovir disoproxil.]
[L01AD01, carmustine, Tenofovir disoproxil may decrease the excretion rate of Carmustine which could result in a higher serum level.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Tenofovir disoproxil.]
[L01EX13, gilteritinib, The serum concentration of Gilteritinib can be increased when it is combined with Tenofovir disoproxil.]
[L01XJ03, glasdegib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Glasdegib.]
[A06AX05, prucalopride, Tenofovir disoproxil may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[B01AC23, cilostazol, Tenofovir disoproxil may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[J01FA09, clarithromycin, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Clarithromycin.]
[N06BA14, solriamfetol, Tenofovir disoproxil may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[L01EN01, erdafitinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The serum concentration of Clobazam can be increased when it is combined with Tenofovir disoproxil.]
[J01DC04, cefaclor, Cefaclor may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DB05, cefadroxil, Cefadroxil may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DC03, cefamandole, Cefamandole may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DB07, cefatrizine, Cefatrizine may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DB04, cefazolin, Cefazolin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Tenofovir disoproxil.]
[J01DC09, cefmetazole, Cefmetazole may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DC06, cefonicid, Cefonicid may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DD12, cefoperazone, Cefoperazone may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DD01, cefotaxime, Cefotaxime may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DC05, cefotetan, Cefotetan may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DC07, cefotiam, Cefotiam may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DC01, cefoxitin, Cefoxitin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DD03, cefsulodin, Cefsulodin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DD02, ceftazidime, Ceftazidime may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DD04, ceftriaxone, Ceftriaxone may increase the nephrotoxic activities of Tenofovir disoproxil.]
[S01AA27, cefuroxime, Cefuroxime may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01EJ02, fedratinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Pitolisant.]
[J01XX12, lefamulin, The serum concentration of Lefamulin can be increased when it is combined with Tenofovir disoproxil.]
[N04CX01, istradefylline, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Istradefylline.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XX09, daptomycin, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Daptomycin.]
[J01DB01, cephalexin, Cephalexin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DB02, cephaloridine, Cefaloridine may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DB03, cephalothin, Cefalotin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DB08, cephapirin, Cefapirin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DB09, cephradine, Cefradine may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Tenofovir disoproxil.]
[N02CC08, lasmiditan, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Lasmiditan.]
[A16AX16, givosiran, Givosiran may increase the nephrotoxic activities of Tenofovir disoproxil.]
[M09AX08, golodirsen, Tenofovir disoproxil may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Tenofovir disoproxil.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tenofovir disoproxil.]
[S01XA12, dexpanthenol, Tenofovir disoproxil may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Tenofovir disoproxil.]
[L01XX72, tazemetostat, The serum concentration of Tazemetostat can be increased when it is combined with Tenofovir disoproxil.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Tenofovir disoproxil.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Tenofovir disoproxil.]
[R02AA03, dichlorobenzyl alcohol, Tenofovir disoproxil may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Tenofovir disoproxil may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[M01AH02, rofecoxib, Rofecoxib may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C08CA16, clevidipine, Tenofovir disoproxil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BD07, dronedarone, The excretion of Tenofovir disoproxil can be decreased when combined with Dronedarone.]
[S03AA08, chloramphenicol, The excretion of Tenofovir disoproxil can be decreased when combined with Chloramphenicol.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Tenofovir disoproxil which could result in a higher serum level.]
[L01EX17, capmatinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Capmatinib.]
[M01AC04, droxicam, Droxicam may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01EX19, ripretinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Ripretinib.]
[V08CA05, mangafodipir, Tenofovir disoproxil may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[M02AA27, dexketoprofen, Dexketoprofen may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Tenofovir disoproxil.]
[P01BA01, chloroquine, Tenofovir disoproxil may decrease the excretion rate of Chloroquine which could result in a higher serum level.]
[L01EX23, pralsetinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AA01, chlorpromazine, Tenofovir disoproxil may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.]
[A10BB02, chlorpropamide, Tenofovir disoproxil may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Tenofovir disoproxil may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[N02BA07, ethenzamide, Ethenzamide may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N02BA03, choline salicylate, Tenofovir disoproxil may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[M01AB08, etodolac, Etodolac may increase the nephrotoxic activities of Tenofovir disoproxil.]
[M02AA06, etofenamate, Etofenamate may increase the nephrotoxic activities of Tenofovir disoproxil.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Tenofovir disoproxil.]
[A16AX20, lonafarnib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Tenofovir disoproxil.]
[M01AX25, chondroitin sulfates, Tenofovir disoproxil may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[J05AJ04, cabotegravir, The excretion of Tenofovir disoproxil can be decreased when combined with Cabotegravir.]
[L04AD03, voclosporin, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Voclosporin.]
[L01EX21, tepotinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Tenofovir disoproxil.]
[M01AE05, fenbufen, Fenbufen may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C01CA19, fenoldopam, Tenofovir disoproxil may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[J01DD15, cefdinir, Tenofovir disoproxil may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[S01JA01, fluorescein, The excretion of Tenofovir disoproxil can be decreased when combined with Fluorescein.]
[N02BG07, flupirtine, Tenofovir disoproxil may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Tenofovir disoproxil.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Tenofovir disoproxil.]
[A02BA01, cimetidine, The excretion of Tenofovir disoproxil can be decreased when combined with Cimetidine.]
[V08CA04, gadoteridol, Tenofovir disoproxil may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[J01MB06, cinoxacin, The excretion of Tenofovir disoproxil can be decreased when combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, Tenofovir disoproxil may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01XA01, cisplatin, Cisplatin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA48, belumosudil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Belumosudil.]
[P01CA03, fexinidazole, The excretion of Tenofovir disoproxil can be decreased when combined with Fexinidazole.]
[V09AB03, ioflupane I-123, Tenofovir disoproxil may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Tenofovir disoproxil may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Tenofovir disoproxil.]
[V09AX06, florbetaben f-18, Tenofovir disoproxil may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[L01EA06, asciminib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Maribavir.]
[D11AH08, abrocitinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Clofazimine.]
[B06AX04, mitapivat, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Mitapivat.]
[N01BB10, levobupivacaine, Tenofovir disoproxil may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01EJ03, pacritinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Tenofovir disoproxil.]
[N06AA04, clomipramine, Tenofovir disoproxil may decrease the excretion rate of Clomipramine which could result in a higher serum level.]
[N03AE01, clonazepam, Tenofovir disoproxil may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[J05AH02, oseltamivir, Tenofovir disoproxil may decrease the excretion rate of Oseltamivir which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH02, clozapine, Tenofovir disoproxil may decrease the excretion rate of Clozapine which could result in a higher serum level.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Tenofovir disoproxil.]
[A10BK06, sotagliflozin, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Sotagliflozin.]
[J01GB12, arbekacin, Arbekacin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[M01AX13, proquazone, Proquazone may increase the nephrotoxic activities of Tenofovir disoproxil.]
[R05DA04, codeine, The excretion of Tenofovir disoproxil can be decreased when combined with Codeine.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Tenofovir disoproxil.]
[J01XB01, colistin, Colistin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DE02, cefpirome, Cefpirome may increase the nephrotoxic activities of Tenofovir disoproxil.]
[A04AA03, tropisetron, Tenofovir disoproxil may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, Tenofovir disoproxil may decrease the excretion rate of Nateglinide which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may increase the nephrotoxic activities of Tenofovir disoproxil.]
[B01AC10, indobufen, Indobufen may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J05AB14, valganciclovir, Tenofovir disoproxil may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Tenofovir disoproxil may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Tenofovir disoproxil may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Tenofovir disoproxil may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Tenofovir disoproxil may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Tenofovir disoproxil may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N02CC05, almotriptan, Tenofovir disoproxil may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M01AH04, parecoxib, Parecoxib may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J02AC02, itraconazole, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Itraconazole.]
[S01AD03, acyclovir, Acyclovir may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N05BA10, ketazolam, Tenofovir disoproxil may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J02AC04, posaconazole, The serum concentration of Posaconazole can be increased when it is combined with Tenofovir disoproxil.]
[A02BC05, esomeprazole, The excretion of Tenofovir disoproxil can be decreased when combined with Esomeprazole.]
[N03AX09, lamotrigine, Tenofovir disoproxil may decrease the excretion rate of Lamotrigine which could result in a higher serum level.]
[N07BC04, lofexidine, Tenofovir disoproxil may decrease the excretion rate of Lofexidine which could result in a higher serum level.]
[M01AB09, lonazolac, Lonazolac may increase the nephrotoxic activities of Tenofovir disoproxil.]
[M02AA31, loxoprofen, Loxoprofen may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DC08, loracarbef, Loracarbef may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C09AA03, lisinopril, Tenofovir disoproxil may decrease the excretion rate of Lisinopril which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Tenofovir disoproxil may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[J01DH02, meropenem, Tenofovir disoproxil may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Tenofovir disoproxil may decrease the excretion rate of Melperone which could result in a higher serum level.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[S02BA08, fluocinolone acetonide, Tenofovir disoproxil may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.]
[M01AG01, mefenamic acid, Mefenamic acid may increase the nephrotoxic activities of Tenofovir disoproxil.]
[S01XA18, cyclosporine, Cyclosporine may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C10AA07, rosuvastatin, The excretion of Tenofovir disoproxil can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, Mofebutazone may increase the nephrotoxic activities of Tenofovir disoproxil.]
[M01AX22, morniflumate, Morniflumate may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C03XA02, conivaptan, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Conivaptan.]
[G04BE09, vardenafil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Vardenafil.]
[M01AH05, etoricoxib, Etoricoxib may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01AX04, dacarbazine, Tenofovir disoproxil may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Tenofovir disoproxil.]
[M01AX01, nabumetone, Nabumetone may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N07BB05, nalmefene, Tenofovir disoproxil may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[S01GX04, nedocromil, Tenofovir disoproxil may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, Tenofovir disoproxil may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[C01DX16, nicorandil, Tenofovir disoproxil may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Tenofovir disoproxil may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[B01AX05, fondaparinux, Tenofovir disoproxil may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[A07EC03, olsalazine, Olsalazine may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N06AA01, desipramine, Tenofovir disoproxil may decrease the excretion rate of Desipramine which could result in a higher serum level.]
[H01BA02, desmopressin, Tenofovir disoproxil may decrease the excretion rate of Desmopressin which could result in a higher serum level.]
[J01DH03, ertapenem, Tenofovir disoproxil may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[M01AE12, oxaprozin, Oxaprozin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N03AF02, oxcarbazepine, The serum concentration of Tenofovir disoproxil can be decreased when it is combined with Oxcarbazepine.]
[N06BA02, dextroamphetamine, Tenofovir disoproxil may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[C01DA05, pentaerythritol tetranitrate, Tenofovir disoproxil may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[P03AC04, permethrin, Tenofovir disoproxil may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Tenofovir disoproxil may decrease the excretion rate of Diazepam which could result in a higher serum level.]
[R05DA08, pholcodine, Tenofovir disoproxil may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Clodronic acid.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Tenofovir disoproxil is combined with Foscarnet.]
[A03AA07, dicyclomine, Tenofovir disoproxil may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, The serum concentration of Didanosine can be increased when it is combined with Tenofovir disoproxil.]
[L01DC04, ixabepilone, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Ixabepilone.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA03, isradipine, Tenofovir disoproxil may decrease the excretion rate of Isradipine which could result in a higher serum level.]
[D07XC04, diflucortolone, Tenofovir disoproxil may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N02BA11, diflunisal, Diflunisal may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Tenofovir disoproxil.]
[C01AA05, digoxin, Tenofovir disoproxil may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02AA03, hydromorphone, Tenofovir disoproxil may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, Tenofovir disoproxil may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The serum concentration of Atazanavir can be decreased when it is combined with Tenofovir disoproxil.]
[H03BC01, potassium perchlorate, Tenofovir disoproxil may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Tenofovir disoproxil may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[V03AB09, dimercaprol, Tenofovir disoproxil may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Tenofovir disoproxil may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N02BB04, propyphenazone, Propyphenazone may increase the nephrotoxic activities of Tenofovir disoproxil.]
[M01AB14, proglumetacin, Proglumetacin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[G02AD02, dinoprostone, The excretion of Tenofovir disoproxil can be decreased when combined with Dinoprostone.]
[C05CA03, diosmin, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Diosmin.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Tenofovir disoproxil.]
[S01AX06, resorcinol, Tenofovir disoproxil may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Tenofovir disoproxil may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[S02AA12, rifamycin SV, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Rifamycin.]
[R06AE09, levocetirizine, Tenofovir disoproxil may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, Tenofovir disoproxil may decrease the excretion rate of Ropivacaine which could result in a higher serum level.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Tenofovir disoproxil.]
[G04BE08, tadalafil, Tenofovir disoproxil may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C02KX02, ambrisentan, The serum concentration of Ambrisentan can be increased when it is combined with Tenofovir disoproxil.]
[C01EB18, ranolazine, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may increase the nephrotoxic activities of Tenofovir disoproxil.]
[H05BA01, salmon calcitonin, Tenofovir disoproxil may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.]
[C01CA07, dobutamine, Tenofovir disoproxil may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[C01CA04, dopamine, Tenofovir disoproxil may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA12, doxepin, Tenofovir disoproxil may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01AA02, doxycycline, Tenofovir disoproxil may decrease the excretion rate of Doxycycline which could result in a higher serum level.]
[A08AA10, sibutramine, Tenofovir disoproxil may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C10AA01, simvastatin, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Simvastatin.]
[A12CA02, sodium sulfate, Tenofovir disoproxil may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Tenofovir disoproxil may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N02CC01, sumatriptan, Tenofovir disoproxil may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[V04CX07, edrophonium, Tenofovir disoproxil may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Tenofovir disoproxil.]
[J01CG02, tazobactam, The excretion of Tenofovir disoproxil can be decreased when combined with Tazobactam.]
[L01AX03, temozolomide, Tenofovir disoproxil may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C09AA02, enalapril, The excretion of Tenofovir disoproxil can be decreased when combined with Enalapril.]
[M01AG02, tolfenamic acid, Tolfenamic acid may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N06AG03, toloxatone, Tenofovir disoproxil may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, Tenofovir disoproxil may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N03AX11, topiramate, Tenofovir disoproxil may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[L02BA02, toremifene, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Toremifene.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX16, venlafaxine, Tenofovir disoproxil may decrease the excretion rate of Venlafaxine which could result in a higher serum level.]
[M01AB04, zomepirac, Zomepirac may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N03AX15, zonisamide, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Zonisamide.]
[L01XA02, carboplatin, Carboplatin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C02AC02, guanfacine, Tenofovir disoproxil may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[L03AX05, pidotimod, Tenofovir disoproxil may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Erythromycin.]
[N05CD04, estazolam, Tenofovir disoproxil may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, The excretion of Tenofovir disoproxil can be decreased when combined with Pantoprazole.]
[G03CA03, estradiol, Tenofovir disoproxil may decrease the excretion rate of Estradiol which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), The excretion of Tenofovir disoproxil can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, Tenofovir disoproxil may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[V08CA03, gadodiamide, Tenofovir disoproxil may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[C01BD05, ibutilide, Tenofovir disoproxil may decrease the excretion rate of Ibutilide which could result in a higher serum level.]
[M01AC06, meloxicam, Meloxicam may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N01AX07, etomidate, Tenofovir disoproxil may decrease the excretion rate of Etomidate which could result in a higher serum level.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Tenofovir disoproxil.]
[L04AD02, tacrolimus, Tacrolimus may increase the nephrotoxic activities of Tenofovir disoproxil.]
[P01AX07, trimetrexate, Tenofovir disoproxil may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Tenofovir disoproxil may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, Tenofovir disoproxil may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.]
[L02AE02, leuprolide, Tenofovir disoproxil may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C10AA03, pravastatin, The excretion of Tenofovir disoproxil can be decreased when combined with Pravastatin.]
[M01CB01, gold sodium thiomalate, Tenofovir disoproxil may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Tenofovir disoproxil may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Tenofovir disoproxil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A02BA03, famotidine, The excretion of Tenofovir disoproxil can be decreased when combined with Famotidine.]
[A16AA01, levocarnitine, Tenofovir disoproxil may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[M01AE04, fenoprofen, Fenoprofen may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N02AB03, fentanyl, Tenofovir disoproxil may decrease the excretion rate of Fentanyl which could result in a higher serum level.]
[R03CC02, albuterol, Tenofovir disoproxil may decrease the excretion rate of Salbutamol which could result in a higher serum level.]
[L01BB06, clofarabine, Tenofovir disoproxil may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[N07AX03, cevimeline, Tenofovir disoproxil may decrease the excretion rate of Cevimeline which could result in a higher serum level.]
[G04BD02, flavoxate, Tenofovir disoproxil may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[N02BG04, floctafenine, Floctafenine may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J02AC01, fluconazole, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Fluconazole.]
[J02AX01, flucytosine, Tenofovir disoproxil may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Tenofovir disoproxil may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[L01BC09, floxuridine, Tenofovir disoproxil may decrease the excretion rate of Floxuridine which could result in a higher serum level.]
[N05CD01, flurazepam, Tenofovir disoproxil may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, Flurbiprofen may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L02BB01, flutamide, Tenofovir disoproxil may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Tenofovir disoproxil may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[S02AA17, fosfomycin, Tenofovir disoproxil may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01BC03, tegafur, Tenofovir disoproxil may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[J05AE10, darunavir, The serum concentration of Darunavir can be increased when it is combined with Tenofovir disoproxil.]
[C03CA01, furosemide, Furosemide may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N05CF04, eszopiclone, Tenofovir disoproxil may decrease the excretion rate of Eszopiclone which could result in a higher serum level.]
[S01AD09, ganciclovir, The excretion of Tenofovir disoproxil can be decreased when combined with Ganciclovir.]
[C10AB04, gemfibrozil, The excretion of Tenofovir disoproxil can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, Tenofovir disoproxil may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Tenofovir disoproxil.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Tenofovir disoproxil.]
[L01EH01, lapatinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, The excretion of Tenofovir disoproxil can be decreased when combined with Glyburide.]
[A10BB07, glipizide, Tenofovir disoproxil may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Tenofovir disoproxil may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.]
[L01EX02, sorafenib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Sorafenib.]
[M01CB04, aurothioglucose, Tenofovir disoproxil may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Tenofovir disoproxil may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, Tenofovir disoproxil may decrease the excretion rate of Fosinopril which could result in a higher serum level.]
[S01EX01, guanethidine, Tenofovir disoproxil may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Tenofovir disoproxil may decrease the excretion rate of Goserelin which could result in a higher serum level.]
[N05AD01, haloperidol, Tenofovir disoproxil may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N05AH04, quetiapine, Tenofovir disoproxil may decrease the excretion rate of Quetiapine which could result in a higher serum level.]
[N06BX13, idebenone, Tenofovir disoproxil may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[M04AA01, allopurinol, Tenofovir disoproxil may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, The excretion of Tenofovir disoproxil can be decreased when combined with Losartan.]
[G03DC01, allylestrenol, Tenofovir disoproxil may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Tenofovir disoproxil.]
[C01CE02, milrinone, Tenofovir disoproxil may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[M02AA26, nimesulide, Nimesulide may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C09AA04, perindopril, Tenofovir disoproxil may decrease the excretion rate of Perindopril which could result in a higher serum level.]
[C02DB02, hydralazine, Tenofovir disoproxil may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Tenofovir disoproxil may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Tenofovir disoproxil may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, Tenofovir disoproxil may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[B05AA07, hetastarch, Tenofovir disoproxil may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[M05BA07, risedronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Risedronic acid.]
[R02AX02, ibuprofen, Ibuprofen may increase the nephrotoxic activities of Tenofovir disoproxil.]
[B05XA08, sodium acetate, Tenofovir disoproxil may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, Tenofovir disoproxil may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Tenofovir disoproxil.]
[R01AD07, tixocortol, Tenofovir disoproxil may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Tenofovir disoproxil.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, Indomethacin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[A11HA07, inositol, Tenofovir disoproxil may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, Tenofovir disoproxil may decrease the excretion rate of Milnacipran which could result in a higher serum level.]
[S01XA28, varenicline, Tenofovir disoproxil may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[A10BH01, sitagliptin, The serum concentration of Sitagliptin can be increased when it is combined with Tenofovir disoproxil.]
[N05BA12, alprazolam, Tenofovir disoproxil may decrease the excretion rate of Alprazolam which could result in a higher serum level.]
[N05CH02, ramelteon, Tenofovir disoproxil may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Tenofovir disoproxil may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[G04BE01, alprostadil, The excretion of Tenofovir disoproxil can be decreased when combined with Alprostadil.]
[J04AC01, isoniazid, Tenofovir disoproxil may decrease the excretion rate of Isoniazid which could result in a higher serum level.]
[J05AX05, inosine pranobex, Tenofovir disoproxil may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[D10BA01, isotretinoin, Tenofovir disoproxil may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[S01AA24, kanamycin, Kanamycin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N01AX03, ketamine, Tenofovir disoproxil may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[B01AC22, prasugrel, Tenofovir disoproxil may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Ketoconazole.]
[M02AA10, ketoprofen, Ketoprofen may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01MB02, nalidixic acid, The excretion of Tenofovir disoproxil can be decreased when combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C07AG01, labetalol, Tenofovir disoproxil may decrease the excretion rate of Labetalol which could result in a higher serum level.]
[N04BB01, amantadine, Tenofovir disoproxil may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A06AX03, lubiprostone, Tenofovir disoproxil may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the nephrotoxic activities of Tenofovir disoproxil.]
[S01AA21, amikacin, Amikacin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[A07DA03, loperamide, The serum concentration of Loperamide can be increased when it is combined with Tenofovir disoproxil.]
[N05BA06, lorazepam, Tenofovir disoproxil may decrease the excretion rate of Lorazepam which could result in a higher serum level.]
[N05AH01, loxapine, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Tenofovir disoproxil may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Tenofovir disoproxil may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[L01BA05, pralatrexate, Tenofovir disoproxil may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Tenofovir disoproxil.]
[N06AA21, maprotiline, Tenofovir disoproxil may decrease the excretion rate of Maprotiline which could result in a higher serum level.]
[C02BB01, mecamylamine, Tenofovir disoproxil may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[M02AA18, meclofenamic acid, Meclofenamic acid may increase the nephrotoxic activities of Tenofovir disoproxil.]
[P01BC02, mefloquine, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Mefloquine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH01, melatonin, The excretion of Tenofovir disoproxil can be decreased when combined with Melatonin.]
[N06DX01, memantine, Tenofovir disoproxil may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Tenofovir disoproxil may decrease the excretion rate of Meperidine which could result in a higher serum level.]
[N01BB03, mepivacaine, Tenofovir disoproxil may decrease the excretion rate of Mepivacaine which could result in a higher serum level.]
[G04BX16, tiopronin, Tenofovir disoproxil may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Paliperidone.]
[A10BA02, metformin, Tenofovir disoproxil may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N07BC02, methadone, Tenofovir disoproxil may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N06BA03, methamphetamine, Tenofovir disoproxil may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, Tenofovir disoproxil may decrease the excretion rate of Methimazole which could result in a higher serum level.]
[L01BA04, pemetrexed, Tenofovir disoproxil may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Tenofovir disoproxil may decrease the excretion rate of Pyridoxine which could result in a higher serum level.]
[L04AX03, methotrexate, Methotrexate may increase the nephrotoxic activities of Tenofovir disoproxil.]
[D05BA02, methoxsalen, Tenofovir disoproxil may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Tenofovir disoproxil may decrease the excretion rate of Methyldopa which could result in a higher serum level.]
[V04CG05, methylene blue, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Methylene blue.]
[G03EK01, methyltestosterone, The excretion of Tenofovir disoproxil can be increased when combined with Methyltestosterone.]
[A03FA01, metoclopramide, Tenofovir disoproxil may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Tenofovir disoproxil may decrease the excretion rate of Metoprolol which could result in a higher serum level.]
[V04CD01, metyrapone, Tenofovir disoproxil may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N02BB03, aminopyrine, Aminophenazone may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N05CD08, midazolam, Tenofovir disoproxil may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[G03XB01, mifepristone, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Mifepristone.]
[J05AH01, zanamivir, Tenofovir disoproxil may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[J01AA08, minocycline, The excretion of Tenofovir disoproxil can be decreased when combined with Minocycline.]
[L03AC01, aldesleukin, Tenofovir disoproxil may decrease the excretion rate of Aldesleukin which could result in a higher serum level.]
[C01BD01, amiodarone, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, Tenofovir disoproxil may decrease the excretion rate of Amitriptyline which could result in a higher serum level.]
[N02AA01, morphine, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Morphine.]
[A04AA05, palonosetron, Tenofovir disoproxil may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L04AB05, certolizumab pegol, Tenofovir disoproxil may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Tenofovir disoproxil may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Tenofovir disoproxil.]
[L04AA06, mycophenolic acid, Tenofovir disoproxil may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[G04CA04, silodosin, The serum concentration of Silodosin can be increased when it is combined with Tenofovir disoproxil.]
[N03AB05, fosphenytoin, The serum concentration of Tenofovir disoproxil can be decreased when it is combined with Fosphenytoin.]
[C07AA12, nadolol, Tenofovir disoproxil may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01CA04, amoxicillin, Tenofovir disoproxil may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[J01CF06, nafcillin, The excretion of Tenofovir disoproxil can be decreased when combined with Nafcillin.]
[V03AB15, naloxone, Tenofovir disoproxil may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N06BA01, amphetamine, Tenofovir disoproxil may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[M02AA12, naproxen, Naproxen may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N06AX21, duloxetine, Tenofovir disoproxil may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N04BX01, tolcapone, Tenofovir disoproxil may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Tenofovir disoproxil is combined with Neomycin.]
[B01AC17, tirofiban, Tenofovir disoproxil may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[J02AA01, amphotericin B, Amphotericin B may increase the nephrotoxic activities of Tenofovir disoproxil.]
[S01AA19, ampicillin, Tenofovir disoproxil may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Tenofovir disoproxil may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Netilmicin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N06AX23, desvenlafaxine, Tenofovir disoproxil may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.]
[J05AB11, valacyclovir, Valaciclovir may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C01CE01, inamrinone, Tenofovir disoproxil may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C08CA05, nifedipine, Tenofovir disoproxil may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, Niflumic acid may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C08CA07, nisoldipine, Tenofovir disoproxil may decrease the excretion rate of Nisoldipine which could result in a higher serum level.]
[R07AX01, nitric oxide, Tenofovir disoproxil may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Tenofovir disoproxil may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, Tenofovir disoproxil may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04BC05, pramipexole, Tenofovir disoproxil may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, Tenofovir disoproxil may decrease the excretion rate of Nitroprusside which could result in a higher serum level.]
[S01AE02, norfloxacin, The excretion of Tenofovir disoproxil can be decreased when combined with Norfloxacin.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Tenofovir disoproxil.]
[A16AX07, sapropterin, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Sapropterin.]
[S02AA16, ofloxacin, The excretion of Tenofovir disoproxil can be decreased when combined with Ofloxacin.]
[N02AA02, opium, Tenofovir disoproxil may decrease the excretion rate of Opium which could result in a higher serum level.]
[G04CA02, tamsulosin, Tenofovir disoproxil may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[C01AC01, ouabain, The excretion of Tenofovir disoproxil can be decreased when combined with Ouabain.]
[M05BA08, zoledronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Zoledronic acid.]
[J01CF04, oxacillin, Tenofovir disoproxil may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[N05BA04, oxazepam, Tenofovir disoproxil may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may increase the nephrotoxic activities of Tenofovir disoproxil.]
[S01AA04, oxytetracycline, The excretion of Tenofovir disoproxil can be decreased when combined with Oxytetracycline.]
[V04CH30, 4-aminohippuric acid, The excretion of Tenofovir disoproxil can be decreased when combined with Aminohippuric acid.]
[J04AB30, capreomycin, Capreomycin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[A07AA06, paromomycin, Paromomycin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[G04BD11, fesoterodine, Tenofovir disoproxil may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Tenofovir disoproxil may decrease the excretion rate of Penbutolol which could result in a higher serum level.]
[S01AA14, penicillin G, The excretion of Tenofovir disoproxil can be decreased when combined with Benzylpenicillin.]
[J01CE09, penicillin G procaine, Tenofovir disoproxil may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, Tenofovir disoproxil may decrease the excretion rate of Pentobarbital which could result in a higher serum level.]
[L01XX08, pentostatin, Tenofovir disoproxil may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Tenofovir disoproxil may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[N02BE03, phenacetin, The excretion of Tenofovir disoproxil can be decreased when combined with Phenacetin.]
[G04BX06, phenazopyridine, Phenazopyridine may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N06AF03, phenelzine, Tenofovir disoproxil may decrease the excretion rate of Phenelzine which could result in a higher serum level.]
[N03AA02, phenobarbital, The serum concentration of Tenofovir disoproxil can be decreased when it is combined with Phenobarbital.]
[V03AB36, phentolamine, Tenofovir disoproxil may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N03AB02, phenytoin, The serum concentration of Tenofovir disoproxil can be decreased when it is combined with Phenytoin.]
[S01AE05, levofloxacin, Tenofovir disoproxil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B02BA01, vitamin K1, Tenofovir disoproxil may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may increase the nephrotoxic activities of Tenofovir disoproxil.]
[C08CX01, mibefradil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Mibefradil.]
[C07AA03, pindolol, Tenofovir disoproxil may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01CA12, piperacillin, Tenofovir disoproxil may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[J05AE01, saquinavir, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Saquinavir.]
[N06BX03, piracetam, Tenofovir disoproxil may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[S01BC06, piroxicam, Piroxicam may increase the nephrotoxic activities of Tenofovir disoproxil.]
[J01DD16, cefditoren, Cefditoren may increase the nephrotoxic activities of Tenofovir disoproxil.]
[A10BG02, rosiglitazone, Tenofovir disoproxil may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Tenofovir disoproxil is combined with Polymyxin B.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The risk or severity of adverse effects can be increased when Ritonavir is combined with Tenofovir disoproxil.]
[A10BH03, saxagliptin, Tenofovir disoproxil may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Tenofovir disoproxil may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[H02AB07, prednisone, Tenofovir disoproxil may decrease the excretion rate of Prednisone which could result in a higher serum level.]
[M04AB01, probenecid, The excretion of Tenofovir disoproxil can be decreased when combined with Probenecid.]
[C01BA02, procainamide, Tenofovir disoproxil may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C10AB05, fenofibrate, Tenofovir disoproxil may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[R06AD02, promethazine, Tenofovir disoproxil may decrease the excretion rate of Promethazine which could result in a higher serum level.]
[C01BC03, propafenone, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Propafenone.]
[A03AB05, propantheline, Tenofovir disoproxil may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Tenofovir disoproxil.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Tenofovir disoproxil.]
[C07AA05, propranolol, Tenofovir disoproxil may decrease the excretion rate of Propranolol which could result in a higher serum level.]
[N02CC04, rizatriptan, Tenofovir disoproxil may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, Tenofovir disoproxil may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N07XX07, dalfampridine, Tenofovir disoproxil may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Tenofovir disoproxil may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Tenofovir disoproxil may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[C01BA01, quinidine, Tenofovir disoproxil may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Quinine.]
[A02BA02, ranitidine, Tenofovir disoproxil may decrease the excretion rate of Ranitidine which could result in a higher serum level.]
[C02AA02, reserpine, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Reserpine.]
[J05AP01, ribavirin, Tenofovir disoproxil may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[S01XA26, riboflavin, The excretion of Tenofovir disoproxil can be decreased when combined with Riboflavin.]
[J04AB02, rifampin, The excretion of Tenofovir disoproxil can be decreased when combined with Rifampicin.]
[N02BA05, salicylamide, Salicylamide may increase the nephrotoxic activities of Tenofovir disoproxil.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the nephrotoxic activities of Tenofovir disoproxil.]
[S01BC08, salicylic acid, Salicylic acid may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N05CA06, secobarbital, Tenofovir disoproxil may decrease the excretion rate of Secobarbital which could result in a higher serum level.]
[J01GB08, sisomicin, Sisomicin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[A12CD01, sodium fluoride, Tenofovir disoproxil may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Tenofovir disoproxil may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Tenofovir disoproxil.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CH02, indigo carmine, Tenofovir disoproxil may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[N05CC01, chloral hydrate, Tenofovir disoproxil may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[N03AG01, valproic acid, The excretion of Tenofovir disoproxil can be decreased when combined with Valproic acid.]
[M05BA01, etidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Etidronic acid.]
[M05BA04, alendronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Alendronic acid.]
[C01DA14, isosorbide mononitrate, Tenofovir disoproxil may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[H02CA04, levoketoconazole, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Levoketoconazole.]
[D10AX03, azelaic acid, Tenofovir disoproxil may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
